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ABSTRACT 
The Panel on Food Additives and Nutrient Sources added to Food provides a scientific opinion evaluating the 
safety  in  use  of  yohimbe  bark  and  its  preparations  originating  from  Yohimbe  (Pausinystalia  yohimbe  (K. 
Schum.) Pierre ex Beille when used in food, e.g. in food supplements. The bark of the plant contains a number of 
indole alkaloids of biological relevance and preparations of yohimbe bark have been traditionally used as general 
tonic, performance enhancer and as an aphrodisiac. Food supplements containing yohimbe bark preparations are 
available nowadays, especially via internet retail. Yohimbine, the major alkaloid of yohimbe bark and raubasine, 
another alkaloid occurring in lower concentrations in the bark, are used as active ingredients in a number of 
medicinal products for which adverse effects are described. The Panel reviewed the available scientific data on a 
possible association between the intake of yohimbe bark and its preparations and potential harmful effects on 
health. When those data were not available, priority was given to yohimbine, as the only alkaloid for which 
occurrence had been shown and quantified in food supplements containing yohimbe bark. The Panel concluded 
that the chemical and toxicological characterisation of yohimbe bark and its preparations for use in food are not 
adequate to conclude on their safety as ingredients of food, e.g. in food supplements. Thus the Panel could not 
provide advice on a daily intake of yohimbe bark and its preparations that do not give rise to concerns about 
harmful  effects  to  health.  An  estimation  of  exposure  to  yohimbine  from  food  supplements  was  performed 
showing that theoretical maximum daily intake may exceed the maximum approved daily dose of yohimbine 
from use as a medicinal product. 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Food Additives and Nutrient 
Sources added to Food (ANS Panel) was asked to deliver a scientific opinion on the evaluation of 
Yohimbe (Pausinystalia yohimbe (K. Schum.) Pierre ex Beille) in accordance with Article 8 (2) of 
Regulation  (EC)  No  1925/2006  on  the  addition  of  vitamins  and  minerals  and  of  certain  other 
substances to foods. This request was triggered by the concerns raised by one of the EU Member 
States on the possible harmful effects associated with the intake of Yohimbe preparations, for example 
in food supplements. 
In particular, EFSA was requested to review the existing scientific data on the possible link between 
the intake of Yohimbe and harmful effects on health, and to provide advice on a tolerable upper intake 
level (UL) for Yohimbe for the general population, and as appropriate, for vulnerable subgroups of the 
population. In the absence of a tolerable upper intake level, the Panel was asked to provide advice on a 
daily intake of Yohimbe that does not give rise to concerns about harmful effects to health. 
In addressing this request, the ANS Panel considered that the term “tolerable upper intake level”, so 
far only used by EFSA to provide guidance on the intake of nutrients, such as vitamins or minerals, 
may  not  be  appropriate  for  botanicals  and  botanical  preparations  being  constituents  of  food 
supplements or other food products, especially in cases where the botanicals/botanical preparations or 
their main components have known medical uses based on scientifically established pharmacological 
properties and/or where the botanicals/ botanical preparations cannot be regarded as components of 
the normal diet. 
Preparations  obtained  from  the  bark  of  Yohimbe  have  been  traditionally  used  in  West  Africa  as 
general tonic, as a performance enhancer for athletes and as an aphrodisiac. The plant Pausinystalia 
yohimbe (K. Schumann) Pierre ex Beille grows in Tropical West Africa (Cameroon, Congo, Gabon, 
Equatorial Guinea, Nigeria). 
Nowadays, despite the use of yohimbe bark and its preparations is specifically prohibited in foods or 
food supplements in several European countries (e.g. United Kingdom, Ireland, Netherlands, Belgium, 
Denmark, Czech Republic) as well as in Canada, Australia and New Zealand, these are nonetheless 
easily available via the internet retail, also in combination with other substances (e.g. caffeine). These 
products are promoted to improve sexual and athletic performance and for the enhancement of sexual 
satisfaction and also for weight loss.  
A  number  of  indole  alkaloids  of  biological  relevance  are  contained  in  the  bark  of  the  trunk  and 
branches  of  Yohimbe,  yohimbine  being  the  main  one.  Yohimbine  is  an  antagonist  acting  at  ʱ2-
adrenoreceptors  found  both  in  the  central  nervous  system  and  at  peripheral  level.  It  enhances 
noradrenaline  release  and  increases  sympathetic  activity.  Other  alkaloids  with  proven  or potential 
biological  activity  have  been  reported  to  occur  in  the  bark,  such  as  raubasine  (also  known  as 
ajmalicine), an ʱ1-adrenoreceptors antagonist, corynanthine and a number of other stereoisomers of 
yohimbine.  
Quantitative data on the chemical composition of the alkaloids in yohimbe bark and its preparations 
are limited and extremely variable, depending on a number of factors, such as growing and harvesting 
conditions of the plant and the analytical method used for quantification. The reported value of total 
alkaloid content of the bark ranges from about 2 to over 150 mg/g. The most frequently reported 
concentration for yohimbine is around 10 mg/g whereas for the individual stereoisomers of yohimbine 
the reported values are in the range of 0.2 to 4.6 mg/g. The concentration of raubasine is reported to be 
around 0.4 mg/g. 
No information was found on the standardisation of the extracts for use in food with regard to the ratio 
of  extracted  material  to  starting  material,  extraction  solvent,  and  content  of  biologically  active 
ingredients. Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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There  are  no  official  inter-laboratory  validated  methods  for  the  determination  of  yohimbine  and 
accompanying alkaloids in food supplements, although a single-laboratory validated method for the 
determination of yohimbine in commercial products has been described. 
In the absence of data for the individual botanical/botanical preparation, the ANS Panel looked at the 
information available in the open literature and at information gathered through the relevant food 
sector organisations and the European Medicines Agency for what concerns the use of yohimbe bark 
and its individual alkaloids as medicinal products.  
No  traditional  medicinal  products  containing  yohimbe  bark  and  its  preparations  appear  to  be 
authorised or registered in the EU, and an assessment report on the safety and efficacy of this botanical 
is not available or currently expected from the Committee on Herbal Medicinal Products (HMPC) of 
the European Medicines Agency.  
Regarding  yohimbe  bark  preparations  in  food  supplements,  some  information  was  found  on  the 
concentration of yohimbine. In studies aimed at measuring the actual content of yohimbine versus the 
one  declared  on  the  label,  it  was  found  that  yohimbine  content  ranged  from  none  up  to  18.8 
mg/serving. Quantitative data for the other yohimbe alkaloids are not available but would also be 
required in view of their known or potential biological activity. 
Yohimbine, the main alkaloid of yohimbe bark, in its hydrochloride form, is the active ingredient of a 
number of medicinal products authorised in several EU countries. It is given orally in the treatment of 
erectile dysfunction in doses of 5 10 mg, 2 3 times daily, the typical treatment period being 8 weeks.  
Raubasine, another alkaloid contained in yohimbe bark, is also the active ingredient of some medicinal 
products. Oral formulations of medicinal products containing raubasine are used as an adjuvant in the 
treatment of peripheral arterial disorders. The dose is 10 20 mg, 2 3 times daily. 
In  the  absence  of  data  on  exposure  to  yohimbe  bark  and  its  preparations,  an  assessment  of  the 
exposure  to  yohimbine  from  food  supplements  was  performed  using  the  data  obtained  from  the 
literature on the measured content of yohimbine in food supplements. The maximum reported content 
of yohimbine in food supplements was multiplied by the number of maximum suggested servings per 
day. According to this estimate, exposure to yohimbine from food supplements intake could be up to 
75 mg/person/day, which is higher than the approved daily dose of yohimbine from use as a medicinal 
product (up to 30 mg/person/day). 
In general, botanicals such as yohimbe bark and botanical preparations such as yohimbe bark extracts 
for use in food supplements should be evaluated based on existing data on the chemical specifications 
and  existing  toxicological  data,  including  read  across  where  appropriate,  for  the  individual 
botanical/botanical  preparation.  Therefore,  the  Panel  gave  priority  to  the  toxicological  studies 
investigating yohimbe bark and its preparations. Furthermore, toxicological data on yohimbine were 
assessed, since this is the main alkaloid in yohimbe bark and the only alkaloid for which occurrence 
had been shown and quantified in food supplements containing yohimbe bark. In this respect the Panel 
noted that interactions of yohimbine with other alkaloids present in the bark may occur.  
No data are available describing the absorption, distribution, metabolism and excretion of yohimbe 
alkaloids after oral administration of yohimbe bark preparations such as extracts. When administered 
to humans, yohimbine is rapidly absorbed and its bioavailability is reported to range widely from 7 % 
to 87 %. In the liver, yohimbine undergoes oxidation to its pharmacologically active metabolite 11-
hydroxy-yohimbine. This metabolic pathway is dependent on the two cytochrome P450 polymorphic 
variants CYP2D6 and CYP3A4. The great interindividual variability in the clinical effects observed 
may be attributable to the differences in the hepatic metabolism. 
No short-term or (sub)chronic toxicity and carcinogenicity studies on yohimbe bark or its preparations 
were available. Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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Regarding raubasine, a study in rats was noted in which administration by gavage at doses of 0, 5, 10, 
20 and 40 mg/kg bw/day for 24 weeks did not produce any effect on body weight, haematology and 
histopathology. 
No  in  vitro  data  on  genotoxicity  studies  of  yohimbe  bark,  its  preparations  or  of  yohimbine  are 
available. 
An in vivo genotoxicity assay in germ cells of male mice was performed after 90 days of treatment 
with an aqueous suspension yohimbe bark powder (yohimbine content not specified). In the same 
study,  a  number  of  parameters  of  male  fertility  were  also  measured.  The  Panel,  however,  had 
reservations about this study and therefore considered that no conclusions could be drawn concerning 
the genotoxicity and reproductive toxicity of yohimbe bark. 
Raubasine  was  negative  in  the  SOS  chromotest  in  E. coli  and  did  not  induce  gene  conversion, 
crossing-over or reverse mutations in the yeast diploid strain XS2316.  
No clinical studies investigating effects of yohimbe bark or its preparations are available. Therefore, 
evidence coming from studies on yohimbine and raubasine was considered. No human data were 
found for the other alkaloids present in yohimbe bark. 
A  published  case  report  describing  a  hypertensive  crisis  following  intake  of  an  herbal  product 
containing yohimbe bark for the treatment of impotence was noted and is suggestive of possible severe 
adverse effects of yohimbine. Based on the information provided in this single case report, it is not 
possible to ascertain the frequency of occurrence. 
Human data encompass several case reports with yohimbine intoxications for which severe symptoms 
(hypertensive crisis, manic symptoms, anxiety, agitation, loss of consciousness) have been described.  
Adverse effects listed in the summary of product characteristics for medicinal products containing 
yohimbine are: headache, nausea, increased urinary urge; insomnia, anxiety, restlessness, irritability 
(common); increase of blood pressure and pulse rate, palpitation, dizziness, vomiting, anorexia, gastric 
complaints,  diarrhoea,  flush,  sweating,  shivering,  allergic  reactions,  nervousness  (uncommon); 
hypotension, tremor, bronchospasm, dysuria, decreased urge, genital pains, exanthema (very rare). 
Several studies in healthy volunteers have been carried out investigating various endpoints such as 
plasma concentrations of noradrenaline, glycerol and non-esterified fatty acids, blood pressure and 
heart rate, all increasing after administration of yohimbine. An antagonising effect on adrenaline-
induced platelet aggregation was also shown. Yohimbine was associated with a dose-related increase 
in impulsive omission errors. In these studies in healthy volunteers 8 mg/person was the lowest dose 
showing antagonism on platelet aggregation without modifying blood pressure, standing heart rate, or 
plasma catecholamine or glucose concentrations. A dose of 12 mg yohimbine/person moderately but 
significantly accelerated supine heart rate.  
According  to  a  study  in  healthy  volunteers,  a  single  oral  dose  of  4  mg  yohimbine/person 
(corresponding to 0.06 mg/kg bw) did not show effects on platelet aggregation and cardiovascular 
parameters as well as plasma catecholamines and glucose concentrations. 
For medicinal products containing raubasine, a number of adverse effects are listed in the summary of 
product characteristics: dizziness, hypotension, sweating, flushing (rare); appearance of  confusion, 
tachycardia, nausea, allergic reactions (occasionally). 
In the human studies evaluated in the present opinion, raubasine did not show adverse effects in oral 
doses less than 10 mg per day (corresponding to approximately 0.15 mg/kg bw/day). Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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The  Panel  noted  that  the  missing  information  include  quantitative  data  on  the  composition  and 
specifications of yohimbe bark and its preparations used in food and food supplements covering other 
alkaloids besides yohimbine, data on the bioavailability of active ingredients from the yohimbe bark 
extract and data on the toxicity of well specified individual preparations of yohimbe bark and the 
major yohimbe bark alkaloids, especially regarding subchronic toxicity, genotoxicity and reproductive 
toxicity. 
The Panel concluded that according to the Guidance on safety assessment of botanicals and botanical 
preparations intended for use as ingredients in food supplements (EFSA SC, 2009) yohimbe bark and 
its preparations belong to the category of botanicals/botanical preparations for which the available data 
are  not  sufficient  to  conclude  on  their  safety  or  possible  health  based  guidance  values  (safety 
assessment based on available knowledge (Level A) revealed need for further data).  
Furthermore the Panel concluded that based on the information on the use of yohimbe bark and its 
preparations in food supplements, estimated exposure to yohimbine could be similar to or higher than 
that at which effects were reported from  the use of yohimbine in medicinal products. Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The German Authorities have raised concerns regarding a potential risk to consumers linked with the 
consumption of foods containing Yohimbe (Pausinystalia yohimbe (K. Schum.) Pierre ex Beille) and 
preparations made from them on the basis of a risk assessment report by the German Federal Institute 
for Risk Assessment (BfR) on Yohimbe (Pausinystalia yohimbe (K. Schum.) Pierre ex Beille). The 
BfR risk assessment report refers to the use of yohimbe bark extract to treat sexual dysfunction and 
erectile  problems  and  yohimbine  as  a  weight-loss  and  performance  enhancement  drug  for 
bodybuilders. The report concludes that “an assessment of the risks of yohimbe bark and preparations 
made from it based on the available data at level A (EFSA SC, 2009) show that the use of yohimbe 
bark and preparations made from it may be harmful to human health, although there is scientific 
uncertainty on this matter”. 
Consequently, the Commission has initiated the procedure under Article 8 (2) of Regulation (EC) No 
1925/2006
4 on the addition of vitamins and minerals and of certain other substances to foods, for 
Yohimbe (Pausinystalia yohimbe (K. Schum.) Pierre ex Beille). 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
In accordance with Article 29(1)(a) of Regulation (EC) No 178/2002
5, the European Commission asks 
EFSA to: 
-  Review  the  existing  scientific  data  on  the  possible  link  between  the  intake  of  Yohimbe 
(Pausinystalia yohimbe (K. Schum.) Pierre ex Beille) and a harmful effect on health. 
- Provide advice on a tolerable upper intake level (UL) for  Yohimbe (Pausinystalia yohimbe (K. 
Schum.) Pierre ex Beille), for the general population, and as appropriate, for vulnerable subgroups of 
the population. 
- In the absence of a tolerable upper intake level (UL), to provide advice on a daily intake of Yohimbe 
(Pausinystalia yohimbe (K. Schum.) Pierre ex Beille) that does not give rise to concerns about harmful 
effects to health.  
INTERPRETATION OF THE TERMS OF REFERENCE BY THE ANS PANEL 
The Panel noted that the term “tolerable upper intake level (UL)” was used by EFSA so far only for 
nutrients, such as vitamins or minerals, to describe the maximum level of total chronic daily intake 
judged to be unlikely to pose a risk of adverse health effects to humans. The Panel considered that the 
use of this term may not be appropriate for botanicals
6 and botanical preparations
7 being constituents 
of food supplements or other food products, especially  in cases where  the botanicals/botanical 
preparations or their main components have known medical uses based on scientifically  established 
pharmacological properties and/or where the botanicals/ botanical preparations cannot be regarded as a 
component of the normal diet. Using the term  “tolerable upper intake level (UL)” for botanicals and 
botanical preparations could lead to the misinterpretation that they could play a similar role in human 
nutrition as minerals and vitamins, which differ from them inter alia in being in general constituents 
of the normal diet and in being in many cases essential. 
                                                       
4 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26-38. 
5 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general 
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures on 
matters of food safety. OJ L 31, 1.2.2002, p. 1-24. 
6 This includes all botanical materials (e.g. whole, fragmented or cut plants, plant parts, algae, fungi and lichens) (EFSA SC, 
2009). 
7 This includes all preparations obtained from botanicals by various processes (e.g. pressing, squeezing, extraction, 
fractionation, distillation, concentration, drying up and fermentation) (EFSA SC, 2009) Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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ASSESSMENT 
 
1.  Introduction 
Following a request from the European Commission to the European Food Safety Authority (EFSA), 
the Scientific Panel on Food Additives and Nutrient Sources added to Food (ANS Panel) was asked to 
provide a scientific opinion on the safety of Yohimbe (Pausinystalia yohimbe (K. Schum.) Pierre ex 
Beille) and preparations made from them when used in food, e.g. in the form of food supplements.  
The  evaluation  is  based  on  the  published  scientific  literature  as  well  as  monographs  and  risk 
assessment reports by national and international authorities, which are available for P. yohimbe and 
their preparations and alkaloids, regarding food or drug use.  
Concerns have been raised regarding a potential risk to consumers associated with the use of yohimbe 
bark or extracts thereof to treat sexual dysfunction and erectile problems and yohimbine as a weight-
loss and performance enhancement drug for bodybuilders (BfR, 2012).  
This risk assessment is carried out in the framework of the procedure under Article 8 (2) of Regulation 
(EC) No 1925/2006 on the addition of vitamins and minerals and of certain other substances to foods, 
for Yohimbe initiated by the European Commission. Article 8 (2) of regulation (EC) No 1925/2006 is 
referring to a possible prohibition, restriction or Community scrutiny of a substance or ingredient by 
placement in Annex III, Part A, B or C of this regulation.  
The risk assessment is carried out according to the EFSA Guidance on safety assessment of botanicals 
and botanical preparations intended for use as ingredients in food supplements (EFSA SC, 2009). 
 
2.  Technical data 
 
2.1.  Identity and nature of source material 
Scientific (Latin) name  Family: Rubiaceae (Bedstraw family) 
Tribe: Naucleeae 
Genus: Pausinystalia L. 
Species: Pausinystalia yohimbe (K. Schumann) Pierre ex Beille 
Synonyms  Pausinystalia  johimbe,  Corynanthe  yohimbe,  Corynanthe  johimbi, 
Corynanthe yohimbi 
Common names  Yohimbe, Johimbe, Liebesbaum, Lustholz, Potenzbaum 
Part used  Bark (Yohimbehe cortex, Cortex Yohimbehe) 
Geographical origin  Tropical West Africa (Cameroon, Congo, Gabon, Equatorial Guinea, 
Nigeria) 
Growth and harvesting 
conditions 
Gathering  from  wild  plants  mostly  in  Cameroon.  No  commercial 
plantations currently exist, although recent experiments have shown 
that clona propagation using shoots or general seed propagation is 
possible (Sunderland et al., 1999).  
 
Information on the identity of the plant was taken from the following references: Kuhlmann, 1999; 
Blaschek et al., 2006; Wink et al., 2008; ACS, 2008, online; USDA ARS, online. 
Yohimbe bark consists of dried bark of the trunk and branches of P. yohimbe (Expanded Commission 
E, online). The dried bark is marketed as flattened or slightly quilled pieces 75 cm long and 4-8 mm 
thick, with an external corky gray-brown layer covered with isolated lichens. In this form the bark Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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shows numerous longitudinal and transverse fissures that are uniform yellowish-brown with short, soft 
fibres like rough velvet (Betz et al., 1995). 
 
2.2.  Chemical composition 
Data on the chemical composition of the bark are scarce and mostly refer to the biologically relevant 
indole alkaloids, the major one being yohimbine. These compounds feature a pentacyclic ring system 
with two nitrogen atoms and five chiral carbon atoms: C3; C15; C16; C17 and C20 (Figure 1) (Le Hir 
et al., 1953). Other reported components of the yohimbe bark are tannins (Gruenwald et al. 2007). 
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Legend: Chiral carbon atoms are indicated with an asterisk (*) 
Figure 1:   General structural formula of yohimbine stereoisomers 
The configuration at C15 is always S
8 and yohimbine and its stereoisomers are broadly divided into 
four groups, namely: normal, pseudo, allo, and epiallo depending on the configurations at C3 and C20. 
They are further subdivided depending on the configurations of the C16 and C17 substituents 
(Chamala, 2010) as shown in Table 1. 
Table 1:   Classification and relative configuration of yohimbine and its stereoisomers based on 
Chamala, 2010. 
Series  C(3)  C(20)  C(16)
  C(17)
  Alkaloid 
normal  S  R 
R  S  yohimbine
(a) 
S  S  corynanthine
(a) 
R  R  β-yohimbine
(a) 
pseudo  R  R 
R  S  pseudoyohimbine
(a) 
S  S  3-epi-corynanthine 
R  R  3-epi-β-yohimbine 
allo  S  S  S  S  ʱ-yohimbine
(a) 
R  S  alloyohimbine
(a) 
epiallo  R  S  S  S  3-epi-ʱ-yohimbine 
                                                       
8 S and R are designations for absolute configuration, i.e. spatial arrangement of the substituent directly attached to the chiral 
centre (atom in a molecule that is bonded to four different chemical species) according to the Cahn-Ingold-Prelog priority 
rules. Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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R  S  3-epi-alloyohimbine 
(a):  Alkaloids identified in yohimbe bark 
 
Alkaloid content data vary, depending e.g. on the age of the plant, the height at which the bark is 
collected and analytical method used (Zanolari et al., 2003; Blaschek et al., 2006). 
According to a number of investigations, the total alkaloid content of the bark is reported to be in the 
range of 2–61 mg/g (Brandt, 1922; Madaus, 1976; Betz et al., 1995; Blaschek et al., 2006; Gruenwald 
et al. 2007). Another source defines that yohimbe bark as a herbal drug should contain from 30 to 150 
mg/g monoterpene indole alkaloids of the yohimbe bark type (Wink et al., 2008). For the extract, the 
content of 95 105 mg/g of total alkaloids, calculated as yohimbine, is described in the pharmaceutical 
literature (Blaschek et al., 2006). 
The main alkaloid of the bark is yohimbine (Table 2). The other alkaloids are primarily yohimbine 
stereoisomers or derivatives thereof (Table 2) (Brandt, 1922; Duke, 1992; Tam et al., 2001; Blaschek 
et al., 2006). 
The content of yohimbine in the bark is given as 7 115 mg/g and is usually around 10 mg/g (Le Hir et 
al., 1953; Betz et al., 1995; Zanolari et al., 2003; Blaschek et al., 2006; Chen et al., 2008). Zanolari et 
al. (2003) reported the yohimbine content in yohimbe bark of 13.03 ± 0.14 mg/g obtained by high 
performance liquid chromatography (HPLC)-ultraviolet (UV) method and 54.2 ± 1.5 mg/g obtained by 
HPLC-atmospheric  pressure  chemical  ionisation  (APCI)/mass  spectrometry  (MS)  method  and 
115.1 mg/g obtained by HPLC-electrospray ionisation (ESI)/MS. 
In the article by Chen et al. (2008) a sample of yohimbe bark (not further specified) was analysed by 
two  different  methods  to give  a yohimbine  content  of 11.7  mg/g  when  analysed  by  non-aqueous 
capillary electrophoresis (NACE) and 11.1 mg/g as analysed by gas chromatography (GC)-MS. 
Other authors (Raman et al., 2013) found the content of yohimbine in the bark using ultra performance 
liquid chromatography (UPLC)-UV-MS to be in the range of 1 to 9.1 mg/g in various samples. 
According to Zanolari et al. (2003) the values reported for yohimbine content may depend largely on 
the method used. 
Yohimbine is very soluble in alcohol and sparingly soluble in water (NTP, 1997;  Blaschek et al., 
2006).  
The presence of yohimbine and its stereoisomers has also been reported in the bark of the following 
plants: Rauwolfia serpentina (L.) Benth (Indian snakeroot), Aspidosperma quebracho-blanco Schltdl. 
(Quebracho), Pseudocinchonia africans Aug. Chev., Coryanthe paniculata Welw. and Pausinystalia 
angolensis  Wernham  and  Rauwolfia  spp.  (Hajonides  van  der  Meulen  and  van  der  Kerk,  1964; 
Chamala, 2010; Expanded Commission E, online). 
 Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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Table 2:   Main  yohimbe  bark  alkaloids  and  relative  synonyms,  CAS  numbers,  molecular  formula  and  molecular  weight,  structural  formulas  and 
reported levels. 
Name  CAS 
Registry 
Number
 
Synonyms
(a)  Molecular 
formula and 
molecular 
weight 
Structural formula
(a) 
 
Content mg/g  
(analytical method) 
Reference 
yohimbine  146-48-5  (+)-yohimbine; aphrodine; corynine; 
quebrachine; yohimban-16ʱ-
carboxylic acid, 17ʱ-hydroxy-, methyl 
ester, yohimbic acid methyl ester 
C21H26N2O3 
354.44 g/mol 
 
8 (TLC on Al oxide) 
traces (TLC on Al oxide) 
Le Hir et al., 1953 
11.5  
22.4 
Hajonides Van Der Meulen 
and Van Der Kerk, 1964 
7.089 (GC-NPD)  Betz et al., 1995 
1 - 9.1 (UPLC-UV/MS)  Raman et al., 2013 
13.03 (HPLC-UV) 
54.2 (HPLC-APCI/MS) 
115.1 (HPLC-ESI-MS 
Zanolari, 2003 
11.7 (NACE) 
11.1 (GC-MS) 
Chen et al., 2008 
13.95 (UHPLC/UV/MS)  Sun and Chen, 2012 
ʱ-yohimbine  131-03-3  methyl (16β,17ʱ,20ʱ)-17-
hydroxyyohimban-16-carboxylate; 
corynanthidine; isoyohimbine; 
mesoyohimbine; rauwolscine 
C21H26N2O3 
354.44 g/mol 
 
traces (TLC on Al oxide)  Le Hir et al., 1953 
4.6  
3.9 
Hajonides Van Der Meulen 
and Van Der Kerk, 1964 
1.62 (NACE) 
1.535 (GC-MS) 
Chen et al., 2008 Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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Name  CAS 
Registry 
Number
 
Synonyms
(a)  Molecular 
formula and 
molecular 
weight 
Structural formula
(a) 
 
Content mg/g  
(analytical method) 
Reference 
β-yohimbine  549-84-8  methyl (16ʱ,17β)-17-
hydroxyyohimban-16-carboxylate; 
amsonine 
C21H26N2O3 
354.44 g/mol 
 
0.3 (TLC on Al oxide) 
traces (TLC on Al oxide) 
Le Hir et al., 1953 
1.75 (NACE) 
1.67 (GC-MS) 
Chen et al., 2008 
pseudoyohimbine  84-37-7  yohimban-16-carboxylic acid, 17-
hydroxy-, methyl ester, (3β,16ʱ,17ʱ); 
ψ-yohimbine 
C21H26N2O3 
354.44 g/mol 
 
0.4 (TLC on Al oxide) 
2.3 (TLC on Al oxide) 
Le Hir et al., 1953 
3.6 
0.2 
Hajonides Van Der Meulen 
and Van Der Kerk, 1964 
corynanthine  483-10-3  methyl (16β,17ʱ)-17-
hydroxyyohimban-16-carboxylate; 
rauhimbine 
C21H26N2O3 
354.44 g/mol 
 
Identified but no 
quantification data on the 
single alkaloid 
Blaschek et al., 2006 Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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Name  CAS 
Registry 
Number
 
Synonyms
(a)  Molecular 
formula and 
molecular 
weight 
Structural formula
(a) 
 
Content mg/g  
(analytical method) 
Reference 
alloyohimbine  522-94-1 
yohimban-16-carboxylic acid, 17-
hydroxy-, methyl ester, 
(16ʱ,17ʱ,20ʱ)-; alloyohimbine (6CI, 
7CI) 
C21H26N2O3 
354.44 g/mol 
 
0.8 (TLC on Al oxide)  Le Hir et al., 1953 
raubasine   483-04-5  ʴ-yohimbine; ajmalicine; 
tetrahydroserpentine; vincaine 
C21H24N2O3 
352.43 g/mol 
 
0.41 (NACE) 
0.39 (GC-MS) 
Chen et al., 2008 
corynantheine  18904-54-6  17,18-secoyohimban-16-carboxylic 
acid, 16,17,18,19-tetradehydro-17-
methoxy-, methyl ester, (E)- (8CI); 
corynan-16-carboxylic acid, 
16,17,18,19-tetradehydro-17-
methoxy-, methyl ester, (16E)- 
C22H26N2O3 
366.45 g/mol 
 
0.056 (NACE) 
0.053 (GC-MS) 
 
Chen et al., 2008 
(a):  From SciFinder, online Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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2.2.1.  Biosynthesis of the yohimbe alkaloids 
Yohimbine  and  its  isomers  are  monoterpenoid-derived  indole  alkaloids  formed  from  the  initial 
condensation  of  tryptamine  with  secologanin  in  the  presence  of  strictosidine  synthase  to  form 
strictosidine. The tryptamine portion of the alkaloid is derived from the decarboxylation of tryptophan 
with tryptophan decarboxylase enzyme. Strictosidine, after deglycosylation with glycosidase, through 
a  series  of  reactive  intermediates  forms  4,21-dehydrocorynantheine  aldehyde  which  undergoes 
isomerisation and reduction to afford yohimbine. Probable biosynthetic pathway for the formation of 
yohimbine alkaloids is presented in Figure 2 (Chamala, 2010). 
 
Figure 2:   Probable biosynthetic pathway for the formation of yohimbine from Chamala, 2010. 
 
2.3.  Specifications 
No specifications for yohimbe bark or its preparations such as extracts for the use in food are known. 
The European Pharmacopoeia (2011) contains specifications for yohimbine hydrochloride (CAS No. 
65-19-0). 
Yohimbine hydrochloride is sparingly soluble in water and practically insoluble in ethanol (96 %) 
(European Pharmacopoeia, 2011). Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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2.4.  Manufacturing process 
Dried bark from the twigs and trunk of the Yohimbe tree is used in its entirety, cut up or ground into 
powder to be used as a drug. Yohimbe bark extracts are available (CAS: 85117-22-2) (Blaschek et al., 
2006, SciFinder, online). There is no information on standardisation of the extracts for use in food 
with  regard  to  the  ratio  of  extracted  material  to  starting  material,  extraction  solvent,  content  of 
biologically active ingredients. Yohimbine, the main component of the bark, can either be obtained 
from the bark or chemically synthesised (Blaschek et al., 2006; Chamala, 2010). 
The isomers of Yohimbine may also be produced synthetically (Chamala, 2010). 
 
2.5.  Methods of analysis in food 
There are no official inter-laboratory validated methods for determining the levels of yohimbine and 
accompanying alkaloids in food. 
In a congress abstract light and scanning electron microscopy studies of yohimbe bark were presented. 
Micromorphology and arrangement of fibres, radially arranged cork cells with thick walls, presence of 
numerous  idioblasts  containing  sand  crystals  of  calcium  oxalate  are  diagnostic  features.  A  few 
variations  in  the  structure  of  fibres  were  observed  and  are  reported.  UPLC-UV-MS  analysis  was 
conducted and the yohimbine content was found to be in the range of 0.1-0.91 % for various samples 
(Raman et al., 2013). 
A single-laboratory validated method for determination of yohimbine in commercial products using 
GC with nitrogen-phosphorous detector (NPD) has been described by Betz et al. (1995). The limit of 
quantitation (LOQ) for this analysis was 0.1 mg/kg, and recoveries were 80 % for liquid products, 65-
70 % for caplets and capsules, and 40 % for fortified protein supplements. 
Zanolari et al. (2003) developed methods based on HPLC and UV and MS techniques with APCI and 
ESI for determination of yohimbine in yohimbe bark and in commercial aphrodisiacs. According to 
the validation results, in the absence of certain yohimbine isomers (such as corynanthine), both HPLC-
APCI/MS and HPLC-ESI/MS appeared to be very selective and robust methods with a sensitivity 20 
times greater than the HPLC-UV method (limit of detection (LOD) = 0.03 ng; LOQ = 0.1 ng). The 
advantages  of  the  HPLC-UV  technique  are  the  greater  range  of  linearity  and  the  possibility  of 
quantifying small quantities of yohimbine isomers (i.e. less than 1 % of the total yohimbine amount). 
Validated GC-MS and NACE methods for analysis of yohimbe alkaloids in the bark of Rubiaceae 
species  were  described  by  Chen  et  al.  (2008).  The  recovery  of  yohimbine  was  91.2-94.0 %  with 
relative standard deviation (RSD) 1.4-4.3 %. The LOD for yohimbine was 0.6 µg/ml by GC-MS and 
1.0 µg/ml by NACE, respectively. 
 
2.6.  Stability  of  the  botanicals  or  botanical  preparations  used  as  ingredients  in  food 
supplements and reaction and fate in food 
No data are available on the stability of yohimbe bark or preparations such as extracts thereof in food. 
Yohimbine  hydrochloride  should  be  kept  in  air  tight  containers,  protected  from  light  (European 
Pharmacopoeia 7.0, 2011). 
 Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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2.7.  Uses and use levels (including products marketed via internet) 
 
2.7.1.  Common foods 
The European Herbal Infusions Association (EHIA) declared that P. yohimbe is not used, as a plant or 
part of plant, by the European industry for herbal and fruit infusions (Letter from EHIA, personal 
communication, April 2013). 
There is no indication that yohimbe bark or its preparations are a component of common food in 
Europe. 
 
2.7.2.  Food supplements 
Dietary supplements of yohimbe bark are commercially available to improve sexual performance and 
enhancement  of  sexual  satisfaction  and  for  weight  loss  purposes  also  in  combination  with  other 
substances  (e.g.  caffeine).  According  to  a  survey  conducted  among  its  members,  the  European 
Responsible Nutrition Alliance (ERNA) declared that yohimbe bark and its preparations are not used 
in food supplements and other food products and as a result of the current situation there has been no 
interest in data demonstrating its safety for food use (Letter from ERNA, personal communication, 
April 2013). 
Thus, the Panel considered that generally these products may not be marketed in Europe but that at 
present they can be easily purchased through the internet.  
Determination of yohimbine in yohimbe bark and related dietary supplements has been carried out in 
two studies from the United States and reported in Table 3.  
Sun and Chen (2012) analysed 13 yohimbe commercial dietary supplement samples by means of an 
ultra high-performance liquid chromatography (UHPLC) method whereas information on another 11 
products are reported by Zanolari et al. (2003). A method based on an HPLC-UV-MS technique was 
used in the latter case and these results are likely to be overestimated by the fact that this method of 
analysis measured the combined amount of yohimbine and corynanthine from yohimbe bark extract. 
Both studies show that the yohimbine content in commercial dietary supplements varies greatly. In 
addition, yohimbine content was not consistent with the amount claimed on the label for most of the 
dietary supplements analysed. Yohimbine content was declared in only two products considered by 
Zanolari et al. (2003) and these values did not correspond with the quantities analytically determined 
(5.8 vs. 4 mg/kg and 1.24 vs. 2.7 mg/kg, respectively). Sun and Chen (2012) noted that only one solid 
sample agreed with the label claim, two samples contained more yohimbe bark compared to the label 
claims (140 % and 180 %, respectively), the rest ranged from 6 % to 50 % of the label claims except 
one which did not have any detectable amount of yohimbine. The two liquid samples contained about 
3 % and 17 % of the label claims, respectively. Consequently, information on the declared content of 
yohimbine or yohimbe bark in food supplements, reported on the label or on the commercial web 
page, is not considered reliable and cannot be used for the assessment of exposure. 
A study conducted by Betz et al. (1995) showed that extracts contain a maximum of 7 % of the 
yohimbine detectable in the bark, with the majority of products having a significantly lower to zero 
detectable yohimbine content. The authors explain this by the very high rate of dilution of the end-
product and by watery extraction methods. Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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The Panel noted that quantitative data for alkaloids other than yohimbine in yohimbe bark containing 
food supplements are missing and would be specially needed for pharmacologically active substances 
such as raubasine
9. 
                                                       
9 It should be noted that the terms raubasine and ajmalicine are synonyms indicating the same alkaloid. In this opinion the 
term raubasine has been preferentially used. Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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Table 3:   Yohimbine in yohimbe bark and dietary supplements 
Dietary supplement 
type 
Yohimbine (analytically determined)  Max No of suggested 
servings per day 
Content of yohimbe bark, extract 
or yohimbine as reported in the 
label (mg/serving) 
Estimated exposure to yohimbine 
(mg/ kg bw/day)
(a) 
Reference 
mg/g or mg/ml  mg/serving  Minimum  Maximum 
AHP
(b) bark  13.95  ±  0.1  -    -  Not available  -  -  Sun and Chen, 2012  
Capsule 
0.96  ±  0.0  0.52  ±  0.05  Not available  -  0.01  0.03  Sun and Chen, 2012 
16.54  ±  0.2  9.93  ±  0.11  Not available  500  0.28  0.57  Sun and Chen, 2012 
5.49  ±  0.1  4.14  ±  0.06  Not available  750  0.12  0.24  Sun and Chen, 2012 
1.78  ±  0.0  1.59  ±  0.09  Not available  600  0.05  0.09  Sun and Chen, 2012 
  NA
(c)     0.50  ±  0.08  4  150 (Yohimbe)  0.03  Zanolari et al., 2003 
0.88  ±  0.0  1.09  ±  0.04  Not available  1200  0.03  0.06  Sun and Chen, 2012 
8.89  ±  0.1  5.33  ±  0.02  Not available  400  0.15  0.30  Sun and Chen, 2012 
  NA
(c)     9.52  ±  0.52  2  250 (extract)/5 (2 %)  0.27  Zanolari et al., 2003 
12.67  ±  0.0  3.91  ±  0.00  Not available  -  0.11  0.22  Sun and Chen, 2012 
  NA
(c)     0.59  ±  0.10  2  125 (bark)  0.02  Zanolari et al., 2003 
  NA
(c)     0.88  ±  0.16  4  Not specified  0.05  Zanolari et al., 2003 
Liquid 
2.4  ±  0.0  2.40  ±  0.01  Not available  1000  0.10  Sun and Chen, 2012 
0.14  ±  0.0  0.14  ±  0.01  Not available  333  0.01  Sun and Chen, 2012 
  NA
(c)     0.99  ±  0.18  3  NA
(c)  0.04  Zanolari et al., 2003 
Mass         2.33  ±  0.06  5  Not specified  0.17  Zanolari et al., 2003 
Tablet 
0.54  ±  0.0  0.68  ±  0.05  Not available
)  800  0.02  0.04  Sun and Chen, 2012 
0.15  ±  0.0  0.65  ±  0.00  Not available  250  0.02  0.04  Sun and Chen, 2012 
  NA
(c)     5.80  ±  1.10  4  200 (extract)/4 (2 %)  0.33  Zanolari et al., 2003 
  NA
(c)     1.24  ±  0.14  2  270 (extract)/2.7  0.04  Zanolari et al., 2003 
7.46  ±  0.0  18.8  ±  0.12  Not available  750  0.54  1.07  Sun and Chen, 2012 
0.51  ±  0.2  0.7  ±  0.00  Not available  100  0.02  Sun and Chen, 2012 
  NA
(c)     1.21  ±  0.18  2  125 (extract)/2.5 (2 %)  0.03  Zanolari et al., 2003 
  NA
(c)     0.53  ±  0.00  3  250 (extract)/5 (2 %)  0.02  Zanolari et al., 2003 
  NA
(c)     3.15  ±  0.34  4  NA
(c)  0.18  Zanolari et al., 2003 
a):  minimum and maximum exposure to yohimbine have been estimated by multiplying the yohimbine content per serving, as analysed, by the minimum and maximum number of suggested 
servings per day for the same dietary supplement type, respectively. A body weight of 70 kg has been used to express the exposure results in mg/day per kg body weight 
(b):  American Herbal Pharmacopoeia 
(c):  Not available Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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2.7.3.  Medicinal products 
 
2.7.3.1.  Use of yohimbe bark and its preparations 
There is only sparse information available from older literature about the use of the herbal substance
10 
or preparations thereof. Decoctions of the bark were used mainly in West Africa as an aphrodisiac to 
stimulate sexual desire and performance (Loewy, 1900; Madaus, 1976). It seems to have been used as 
a local anaesthetic, a mild stimulant to prevent drowsiness, a hallucinogen, a treatment for angina, a 
hypertensive, a general tonic, a treatment for intestinal worms, a performance enhancer for athletes, 
and to increase the clarity of singers‟ voices during long cultural festivals (Clark and Sunderland, 
2004).  
From old literature it could be found that medicinal products containing yohimbe bark or preparations 
thereof,  including  yohimbine  as  isolated  substance  (also  as  combination  products)  were  on  the 
European market for over 100 years (Arends and Zörnig, 1938).  
In the EB6 (1953) the usage of the bark of P. yohimbe was mentioned. Commission E
11 (Blumenthal et 
al., 1998) did not recommend the usage of yohimbe bark because of insufficient proof of efficacy and 
the unforeseeable correlation between risk and benefit for the indications sexual disorders, as an 
aphrodisiac, for feebleness and exhaustion. 
From data provided by 16 out of 30 European Economic Area (EEA) Member States during a recent 
survey  conducted by the European Medicines Agency ( EMA) it appears that no mono ingredient 
(traditional) herbal medicinal products containing herbal substances/preparations from P. yohimbe are 
authorised or registered in the EU (Letter from EMA, personal communication, April 2013). 
 
2.7.3.2.  Use of single alkaloids from yohimbe bark 
Information on existing authorised medicinal products containing the individual alkaloids contained in 
the yohimbe bark have been gathered by the EMA from 16 EEA Member States and are summarised 
in Table 4. The table does not contain information on homeopathic products and on products not for 
oral use. 
                                                       
10 In this opinion the term „herbal substance‟ is used as defined in Directive 2001/83/EC, i.e.: “All mainly whole, fragmented 
or cut plants, plant parts, algae, fungi, lichen in an unprocessed, usually dried, form, but sometimes fresh. Certain exudates 
that have not been subjected to a specific treatment are also considered to be herbal substances. Herbal substances are 
precisely defined by the plant part used and the botanical name according to the binomial system (genus, species, variety 
and author)”. 
11 Commission E is a scientific expert committee for herbal medicinal products  providing support to the German Federal 
Institute for Drugs and Medical Devices in drafting monographs for herbal preparations. Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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Table 4:   Summary of information reported for the authorisation medicinal products for oral use containing yohimbine or raubasine as single ingredient. 
Substance  Posology 
(a)  Therapeutic indications
 (a)  Contraindications and warnings 
(a)  Adverse effects 
(a) 
  Single dose 
range 
Daily dose 
range       
yohimbine HCl  5 mg (may be 
increased to 
10 mg) 
10-15 mg 
(may be 
increased to 
30 mg) for at 
least 8 weeks 
(psychogenic) erectile dysfunction; 
male climacterium 
or 
Disorders of the sexual potency, e.g. 
of the potentia coeundi; libido 
disorders; reduced reflex agitation of 
the lumbosacral mark; general and 
sexual-specific symptoms of the male 
climacterium. 
or 
supportive treatment of mild to 
moderate erectile dysfunction in the 
context of other therapeutic actions 
Hypersensitivity to the active ingredient. 
Cardiac disorders (especially heart disease, 
tachycardic arrhythmia). 
Hypertension, hypotension. 
Greatly impaired kidney or liver function. 
Ulcer (stomach or intestine). 
Glaucoma. 
Psychiatric disorders, particularly mood 
disorders and anxiety. 
Concomitant use of central nervous acting 
drugs. 
There exist no adequate clinical experiences 
with treatment in women. It is also not 
possible to determine effects on a fetus during 
pregnancy. Not be used in women. 
Not indicated for treatment in patients less 
than 18 years. 
Warning: the oral intake of 200 mg 
yohimbine hydrochloride led to intoxication 
symptoms (e.g. with weakness, general 
paresthesia, loss of coordination and memory 
performance, epileptic seizures, headaches 
with dizziness, tremor, palpitations and 
anxiety, chest pain) 
The usage may lead to positive results in 
doping tests. 
Cardiac disorders 
Uncommon: increase of blood pressure and 
pulse rate, palpitation 
Very rare: hypotension 
Nervous system disorders 
Common: headache 
Uncommon: dizziness 
Very rare: tremor 
Respiratory, thoracic and mediastinal 
disorders 
Very rare: bronchospasm 
Gastrointestinal disorders 
Common: nausea 
Uncommon: vomiting, anorexia, gastric 
complaints, diarrhoea 
Renal and urinary disorders 
Common: increased urge 
Very rare: dysuria, decreased urge, genital 
pains 
Skin and subcutaneous tissue disorders 
Uncommon: flush 
Very rare: exanthema 
General disorders 
Uncommon: sweating, shivering 
Immune system disorders 
Uncommon: allergic reactions 
raubasine  10-20 mg  20-60 mg  Adjuvant  in  the  treatment  of 
peripheral arterial disorders 
Hypersensitivity to the active substance. 
Serious heart disease. 
Haemorrhagic  syndrome  or  intracranial 
hypertension. 
Uncompensated  heart  failure,  valvular 
stenosis,  significant  reduction  of  the 
pulmonary circulatory bed, glaucoma. 
First three months of pregnancy. 
During or within two weeks after treatment 
with MAOIs 
Rare:  dizziness,  hypotension,  sweating, 
flushing 
Occasionally:  appearance  of  confusion, 
tachycardia, nausea, allergic reactions 
In the case of heart disease or other general 
disorders  may  require  discontinuation  of 
therapy. 
(a):  As reported in the Summary of Product Characteristics of the authorised medicinal products. Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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2.8.  Exposure 
 
2.8.1.  Exposure via food supplements 
Exposure to yohimbine from food supplements has been estimated by multiplying the number of 
suggested servings per day by the yohimbine content per serving, as analysed by Zanolari et al. (2003) 
and Sun and Chen (2012) as reported in Table 3. Due to the fact that the number of suggested servings 
per day was only available for the food supplements analysed by Zanolari et al. (2003) the minimum 
and maximum serving, within those reported for the same dietary supplement type, was used in the 
other cases. For example, in the case of tablets the number of servings per day ranges from 2 to 4. 
These two figures were used for all dietary supplements served as tablets to estimate minimum and 
maximum acute exposure to yohimbine, respectively. As suggested by the Scientific Committee of 
EFSA (EFSA SC, 2012) a body weight of 70 kg has been used in this opinion as the default value to 
express the exposure results in mg/kg bw/day. Maximum daily exposure to yohimbine was estimated 
as up to 1.07 mg/kg bw, corresponding to 75 mg/person for a 70 kg adult consuming in a day 4 tablets 
containing 18.8 mg of yohimbine each (the highest measured value reported in the literature). 
 
2.8.2.  Other sources of exposure (medicinal products) 
As shown in Table 4, the single dose and the daily dose of yohimbine in the form of the hydrochloride 
is 5 10 mg per single dose and 10 30 mg per daily dose, corresponding to approximately 0.14 to 0.43 
mg/kg bw/day (calculated using a default value of 70 kg bw according to EFSA SC, 2012). 
 
2.9.  Information on existing authorisations, evaluations and regulations 
P. yohimbe is listed in the EFSA Compendium of Botanicals reported to contain naturally occurring 
substances of possible concern for human health when used in food and food supplements (EFSA, 
2012). 
No records for yohimbe bark and its preparations can be found in the EU Register on nutrition and 
health claims (EC, online). 
The EMA has confirmed that no monographs or assessment reports on safety/efficacy are available or 
currently expected from the Committee on Herbal Medicinal Products (HMPC) and that yohimbe bark 
is not on the HMPC priority list. It is important to note that one of the reasons for the lack of priority is 
due  to  concerns  about  the  safety  and  known  risks  associated  with  the  content  and  use  of  these 
substances. The HMPC does not normally prioritise substances with a predictable negative outcome of 
the benefit-risk assessment in line with provisions of Directive 2001/83/EC
12 for traditional herbal 
medicinal products, which includes the provision to establish a plausible and safe medicinal use under 
specified conditions suitable for self -medication without medical supervision.   (Letter from EMA, 
personal communication, April 2013). 
P.  yohimbe  appears  on  the  former  European  Commission‟s  Committee  for  Proprietary  Medicinal 
Products list of Herbal drugs with serious risks, dated 1992
13 as “Drugs with toxic principles, where a 
more detailed discussion concerning the benefit/risk ratio is necessary” (alkaloid containing plants 
requiring  a  benefit  risk  assessment  during  the  revision)”.  In  a  statement  from  2005,  the  HMPC 
provided clarification on how this list should be read today (EMA, 2005). 
                                                       
12 Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating 
to medicinal products for human use. OJ L 311, 28.11.2011, p.67-128. 
13 http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/09/WC500111303.pdf  Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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A response of 16 EEA Member States to EMA's request for information indicates that currently there 
are no medicinal products containing yohimbe bark or extracts thereof registered in these countries. 
Few Member States have registered medicinal products containing yohimbine for oral use (tablets). 
There is a single registered medicinal product containing raubasine in Italy (peroral drops or coated 
pills). 
In Ireland, the use of Yohimbe is not permitted in Traditional Herbal Medicinal Products, as it would 
be controlled as a prescription medicine under the terms of the Medicinal Products Regulations. 
The  United  Kingdom  does  not  consider  any  products  containing  P.  yohimbe  or  yohimbine  to  be 
classified as foods. In the UK the sale and supply of botanicals containing P. yohimbe are controlled 
under the Medicines (Retail Sale or Supply of Herbal Plants Remedies) Order 1977 SI 2130. 
The use of the bark of P. yohimbe is prohibited in the production of foods in the Czech Republic.
14 
The use of  P. yohimbe and its alkaloids is not authorised as food or food supplements in Belgium 
(Royal Decree of 29 August 1997). 
Food supplements with P. yohimbe herbal substance/herbal preparations are not allowed on the Dutch 
market based on the Warenwetbesluit Kruidenpreparaten (Letter from EMA, personal communication, 
April 2013). 
The  Austrian  food  codex  (Codex  Alimentarius  Austriacus,  Österreichisches  Lebensmittelbuch) 
includes the species P. johimbe in a list of plants not to be used for the production of herbal teas.
15 
In Germany, yohimbe bark is the subject of a negative (unapproved) monograph in the Commission E 
due to lack of data and safety concern (Blumenthal et al., 1998). 
The Danish Drogelisten lists Yohimbe (under the synonym Corynanthe johimbe K. Schum) as a plant 
that is unacceptable as food regardless of amount (DTU, online). 
Health  Canada's  drugs  directorate  policy  on  herbals  used  as  non-medicinal  ingredients  in  non-
prescription drugs in human use includes Yohimbe (Corynanthe yohimbe, P. yohimbe) in the list of 
herbs unacceptable as non-medicinal ingredients in oral use products (Health Canada, 1995, online). 
Health Canada's guidance document Drugs Currently Regulated as New Drugs includes yohimbine as 
aphrodisiac in The New Drugs List (Health Canada, 2012a, online). 
Yohimbine or its salts are included in the draft  of the proposed Prescription Drug List of Health 
Canada for both human and veterinary use (Health Canada, 2012b, online). 
The Australia New Zealand Food Standards Code lists in the Standard 1.4.4 (Prohibited and Restricted 
Plants  and  Fungi)  the  species  P.  yohimbe,  syn.  Coryanthe  yohimbe  (yohimbe)  in  the  schedule  of 
prohibited plants and fungi, stating that these plants or fungi, or a part or a derivative of a plant or 
fungus, or any substance derived therefrom, must not be intentionally added to food or offered for sale 
as food.
16 
                                                       
14 225. Vyhláška, kterou se stanoví požadavky na doplňky stravy a na obohacování potravin. Sbírka Zákonů Česká Republika 
30.06.2008, Částka 71, p. 3230-3242. 
See the regulation: vyhláška č. 225/2008 Sb. (Annex 4). www.mvcr.cz/soubor/sb071-08-pdf.aspx 
15 Österreichisches Lebensmittelbuch, Codexkapitel B 31 – Tee und teeähnliche Erzeugnisse, Anhang II – Liste der für die 
Herstellung teeähnlicher Erzeugnisse nicht verwendeter Pflanzen bzw. Pflanzenteile. 
16 Australia New Zealand Food Standards Code. Standard 1.4.4 Prohibited and Restricted Plants and Fungi. Federal Register 
of Legislative Instruments F2011C00580. Issue 124. Prepared on 11.07.2011. Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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Yohimbine and preparations containing yohimbine are listed as aphrodisiacs in a schedule of goods 
the  importation  of  which  is  prohibited  by  the  Customs  (Prohibited  Imports)  Regulations  1956  of 
Australia.
17 
 
3.  Biological and toxicological data 
In the following sections, priority will be given to the toxicological studies investigating yohimbe bark 
and its preparations. Since yohimbine is the main alkaloid of yohimbe bark and the only alkaloid for 
which  occurrence  has  been  measured  in  food  supplements  containing yohimbe  bark,  studies with 
yohimbine in particular are also considered.  
The Panel noted that other alkaloids could be present in yohimbe bark containing food supplements 
and  given  the  known  pharmacological  properties  of  raubasine  and  its  possible  occurrence,  also 
considered these data. 
The Panel noted that stereoisomers of yohimbine occurring in the bark may have biological activity 
(Tanaka and Starke, 1980; Timmermans et al., 1981, Chamala, 2010), however no relevant in vivo 
data were available for assessment. 
 
3.1.  Absorption, distribution, metabolism and excretion (ADME) 
 
3.1.1.  Yohimbe bark and its preparations 
There  are  no  available  data  describing  the  ADME  of  yohimbe  alkaloids  after  administration  of 
yohimbe bark preparations such as extracts. 
 
3.1.2.  Yohimbine and other yohimbe bark alkaloids (raubasine and corynanthine) 
In vitro study 
The absorption of yohimbine, raubasine and corynanthine as chemical constituents of some traditional 
Chinese medicines was investigated in an in vitro study using Caco-2 cell monolayers as a human 
intestinal epithelial cell model (Ma and Yang, 2008). The permeability of the three alkaloids was 
studied measuring their influx from apical side to basolateral side and the efflux from basolateral side 
to apical side and their correlation with the partition coefficient. The three alkaloids were measured by 
high performance liquid chromatography coupled with UV detection. The ratio of efflux to influx 
permeability  of  yohimbine,  raubasine  and  corynanthine  were  1.29,  0.54  and  1.28,  respectively. 
According to the authors, these compounds can be transported and absorbed across the human Caco-2 
cells monolayers, and the oil-water partition coefficient would play key roles in the transport and 
absorption of the three alkaloids. 
Animal studies 
The distribution and metabolism of yohimbine was investigated in mice receiving an intraperitoneal 
(i.p.) administration of yohimbine tritiated on methyl (10 mg/kg bw, 250 μCi) (Ho et al., 1971). The 
labelling penetrated rapidly the brain (10 minutes after dosing). There was no marked differential 
distribution of tritium in the different topographical regions of  the brain. Twenty-four hours after 
                                                       
17 Customs (Prohibited Imports) Regulations 1956 Statutory Rules 1956 No. 90 as amended. Prepared by the  Office of 
Parliamentary Counsel. Federal Register of Legislative Instruments F2013C00003. Prepared 01.01.2013 Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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injection most of the radioactivity was located in brain, kidneys, liver, intestine and muscle. At least 
two radioactive unidentified metabolites were found in the extracts of liver and spleen or in urine. 
The concentration of yohimbine in serum and brain of conscious Sprague-Dawley rats at various times 
after  intravenous  (i.v.)  injection  of  1  mg/kg bw  of  yohimbine  was  measured  using  HPLC  with 
fluorescence detection (Hubbard et al., 1988). The serum concentration-time profile of yohimbine was 
biphasic with a rapid distribution phase (half-time approximately 3 minutes) followed by a very slow 
elimination phase (half-time 16.3 hours). The clearance of yohimbine was 11 ml/h/kg, and the volume 
of distribution was 259 ml/kg. Increasing doses (0.3, 1 and 3 mg/kg bw, i.v.) of yohimbine produced 
non-linear increases in serum yohimbine concentration. Yohimbine entered the brain rapidly (5 000 
ng/g at 5 min after dosing) and had a slow elimination rate from the brain (half-time of 7.7 hours). In 
contrast to serum yohimbine concentration, in the brain increasing doses of yohimbine (0.3, 1 and 
3 mg/kg bw,  i.v.)  produced  linear  increases  in  yohimbine  concentration,  a  phenomenon  which  is 
consistent with concentration-dependent binding of yohimbine to plasma proteins. 
There were no identified data of ADME in animals following oral administration of yohimbine. 
Human studies 
The kinetic disposition of yohimbine following oral administration was investigated in eight young 
male subjects receiving a single oral dose of 10 mg yohimbine hydrochloride (Owen et al., 1987). 
Results from this study showed that yohimbine was very rapidly absorbed (half-time 11 minutes) in 
the systemic circulation and rapidly eliminated from the plasma (half-time 36 minutes). The authors 
reported that the clearance of yohimbine from plasma was constant over approximately 10 elimination 
half-lives, thus suggesting that distribution into a second distinct pharmacokinetic compartment was 
not responsible for the rapid decline in plasma yohimbine levels. It was also reported that yohimbine 
did  not  undergo  direct  urinary  excretion,  as  less  than  1 %  of  the  dose  was  recovered  as  parent 
compound in the urine within 24 hours. These results suggest that yohimbine is eliminated primarily 
through metabolism. 
Pharmacokinetic profiles were determined in seven healthy young male subjects following single oral 
or i.v. doses of 10 mg of yohimbine hydrochloride (Guthrie et al., 1990). The results from this study 
showed that yohimbine was rapidly eliminated (half-time of 35 minutes and 40 minutes following oral 
and i.v. administration, respectively). Following i.v. administration, the data fit a two-compartment 
pharmacokinetic model, with a very rapid distribution phase (half-time approximately 6 min). Both the 
oral and the intravenous yohimbine clearance values were high, but oral clearance values were much 
higher (mean 9.77 ml/min/kg i.v. versus 55.9 ml/min/kg oral). The data on the oral bioavailability 
showed great variability, ranging from 7 % to 87 % (mean value was 33 %). According to the authors, 
the incomplete oral bioavailability of yohimbine may reflect either incomplete absorption from the 
gastrointestinal  tract  or  a  hepatic  first  pass  effect.  In  conclusion,  although  yohimbine  is  rapidly 
absorbed when given orally, the bioavailability is quite variable. 
Le Verge et al. (1992) demonstrated the existence of at least two metabolites of yohimbine in plasma 
or urine of orally or i.v. treated humans. The method used, a normal-phase HPLC combined to NMR 
and mass spectral analyses, allowed the identification of yohimbine and its hydroxylated metabolites, 
10-hydroxyyohimbine  and  11-hydroxyyohimbine,  in  biological  samples.  The  extraction  yields  of 
yohimbine,  10-hydroxyyohimbine  and  11-hydroxyyohimbine  from  plasma  were  91.8,  45.3  and 
17.8 %, respectively, and their respective within-day reproducibility were 3.8, 1.4 and 5.9 %. The 
between-day  reproducibility  for  yohimbine  at  the  concentrations  of  1  and  10 ng/ml  were  8.9  and 
6.4 %, respectively. The accuracy of the method for yohimbine at concentrations of 1 and 10 ng/ml 
was 5.1 and 2.3 %, respectively. The limits of quantification of yohimbine, 10-hydroxyyohimbine and 
11-hydroxyyohimbine were 0.1, 0.5 and 1 ng/ml, respectively. 
The pharmacokinetics of yohimbine and its sympatho-adrenal effects as an  2-adrenergic receptor 
antagonist were studied in 13 young, healthy, male volunteers after an intravenous bolus dose of 0.25 Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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or 0.5 mg/kg bw (Hedner et al., 1992). The results showed that yohimbine was rapidly distributed 
(half-time ranging from 0.4 and 18 minutes). The elimination half-time had greater variability, ranging 
from 15 minutes to 2.5 h. The average volume of distribution (Vss) was 74 l, (ranging from 26 to 
127 l). As previously observed, only 0.5 to 1 % of unchanged yohimbine was found in the urine, 
indicating that the major part of the drug was eliminated by hepatic clearance. Total plasma clearance 
was  117  l/h,  which  exceeded  the  hepatic  plasma  flow.  The  authors  considered  these  findings  as 
suggestive  of  the  fact  that  yohimbine  is  a  high  extraction  drug  with  considerable  extra-hepatic 
metabolism. Fractional urine sampling revealed that 0.5 1% of unchanged yohimbine was excreted in 
urine in a biphasic manner. The data also suggested the existence of a slower elimination phase, with a 
half-time of 13 hours. With regard to the sympatho-adrenal effects of yohimbine, a three-fold increase 
in the plasma concentration of noradrenaline was reported 15 minutes after the yohimbine injection. 
Plasma  adrenaline  and  neuropeptide  Y  (NPY)-like  immunoreactivity  remained  unchanged.  The 
plasma concentration-effect relationship of the changes in circulating noradrenaline followed counter-
clockwise  hysteresis.  According  to  the  authors,  the  results  showed  that  the  hyperadrenergic  state 
elicited by therapeutic doses of yohimbine is due to an interaction with noradrenaline but not to release 
of adrenaline or NPY in man. 
Berlan et al. (1993) investigated the  2-adrenoreceptor antagonist properties of the two hydroxylated 
metabolites  of  yohimbine  in  man  (10-hydroxyyohimbine  and  11-hydroxyyohimbine)  on  the  2-
adrenoreceptors of human platelets and adipocytes. The effects observed were compared to those of 
yohimbine.  Yohimbine  and  11-hydroxyyohimbine  exhibited  similar  2-adrenoreceptor  affinity  in 
biological  studies  i.e.  inhibition  of  adrenaline-induced  platelet  aggregation  and  inhibition  of 
antilipolysis induced by an  2-adrenoreceptor agonist (UK14304) in adipocytes. Yohimbine and the 
two metabolites displaced a labelled selective  2-adrenoreceptor antagonist (
3H-RX 821002) binding 
with equivalent affinities in platelet and adipocyte membranes with the following order of potency: 
yohimbine > 11-hydroxyyohimbine > 10-hydroxyyohimbine. However, when binding studies were 
carried out in binding buffer supplemented with 5 % albumin, the apparent affinity of yohimbine was 
reduced about 10-fold and was similar to that of 11-hydroxyyohimbine. Yohimbine and its metabolites 
were bound to different extents to plasma proteins, the bound fraction being 82 %, 43 % and 32 % 
respectively for yohimbine, 11-hydroxyyohimbine and 10-hydroxyyohimbine. These results show that 
the  main  hydroxylated  metabolite  of  yohimbine  in  man  (11-hydroxyyohimbine)  possesses  2-
adrenoreceptor antagonist properties. According to the authors, the discrepancies found in binding 
studies (i.e. 10 fold lower affinity of 11-hydroxyyohimbine than yohimbine for  2-adrenoreceptor 
antagonist  properties)  were  attributable  to  the  higher  degree  of  binding  of  yohimbine  to  plasma 
protein. 
A study was conducted to examine tolerability and pharmacodynamics of single doses of yohimbine in 
healthy volunteers using measures of mood, heart rate, blood pressure, and serum catecholamine levels 
(Grasing et al., 1996). Participants were given single oral doses of yohimbine hydrochloride (5.4, 10.8, 
16.2 and 21.6 mg). Plasma concentrations of yohimbine, adrenaline, noradrenaline and 3-methoxy-4-
hydroxyphenylethylene-glycol (MHPG) were quantified by means of HPLC. Yohimbine was well 
tolerated  and  rapidly  absorbed  and  eliminated.  Dose-related  increases  in  the  area  under  the 
concentration-time  curve  (AUC)  were  observed,  associated  with  more  pronounced  effects  on  the 
parameters measured. Administration of yohimbine in the presence of a high fat meal diminished both 
the rate and extent of drug absorption. Significant inter-individual variability in the pharmacokinetic 
parameters  of  yohimbine  was  observed,  with  some  individuals  exhibiting  greatly  increased  oral 
bioavailability  of  yohimbine.  The  results  indicate  that  higher  doses  of  yohimbine  are  both  well 
tolerated and produce dose-related increases in AUC, which are associated with more pronounced 
autonomic effects.  
Sturgil et al. (1997) determined the safety, pharmacodynamic response, and single- and multiple-oral 
dose pharmacokinetic profile of yohimbine hydrochloride. In this study, thirty-two healthy volunteers 
were given yohimbine at doses of, 5.4 mg, 3 times/day; 10.8 mg, 3 times/day; 16.2 mg, 3 times/day, or 
21.6 mg 2 times/day, for six days. Plasma catecholamine levels and mood/anxiety-inventory scores Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
 
EFSA Journal 2013;11(7):3302  26 
were measured. The pharmacokinetic profile of yohimbine was determined after the first and last dose. 
Yohimbine exhibited one-compartment elimination in most subjects, with dose-dependent increases in 
the  maximal  concentration  (Cmax)  and  in  the  AUC.  The  authors  reported  no  evidence  of  drug 
accumulation. At least two subjects in each treatment group exhibited two-compartment elimination of 
yohimbine,  however  at  day  7  of  the  study  no  significant  increases  of  AUC,  Cmax,  and  terminal 
elimination  half-time  were  recorded.  The  reported  increase  in  plasma  catecholamine  levels  was 
significantly correlated to both the average yohimbine AUC and Cmax, but there were no significant 
effects on heart rate, blood pressure, or anxiety/mood-inventory scores. The single- and multiple-dose 
pharmacokinetic  profile  of  yohimbine  exhibits  a  substantial  degree  of  interindividual  and 
intraindividual variability, possibly resulting from variability in first-pass and hepatic metabolism. 
The  pharmacokinetics  of  yohimbine  and  its  two  metabolites,  10-hydroxyyohimbine  and  11-
hydroxyyohimbine, were investigated in 12 healthy male subjects after administration of yohimbine (5 
mg, i.v. followed by 8 mg, oral) (Le Corre et al., 1999). Among the subjects treated, one was found to 
be a slow hydroxylator of yohimbine. The oral bioavailability of yohimbine was found to be low and 
extremely variable (22.3 ± 21.5 %). The oral absorption was also reported to be low by the authors, 
possibly due to the formulation used in this study Total plasma clearance of yohimbine following 
intravenous  dosing  was  0.728  ±  0.256  ml/min  whereas  renal  clearance  was  negligible  (0.001  +- 
0.002 ml/min). Based on the steady-state volume of distribution (Vss), yohimbine had a relatively low 
distribution (Vss 23.2 ± 12.1 l). The overall renal excretion of yohimbine, 10-hydroxyyohimbine and 
11-hydroxyyohimbine, expressed as percent of the dose of yohimbine administered, were not different 
following intravenous and oral dosing, and were around 0.1, 0.2 and 14 %, respectively. Following 
intravenous dosing of yohimbine, the mean apparent terminal half-life of 11-hydroxyyohimbine (347 
± 63 min) was almost four times higher than that of yohimbine (91.0 ± 33.6 min), suggesting an 
elimination rate-limited kinetics for 11-hydroxyyohimbine. 
Le Corre et al. (2004) investigated the differences in the metabolism of yohimbine and how these 
variations influence the sympathetic effects exerted by yohimbine. The study was conducted in 172 
individuals (85 men; 87 women) who were administered yohimbine as intravenous infusion (initial 
bolus:  125 μg/kg bw  for  three  minutes,  followed  by  1 μg/kg bw/min  for  12  minutes).  Plasma 
yohimbine and its metabolite 11-hydroxyyohimbine were measured, showing greater than 1000-fold 
variability, with 17 individuals showing no metabolism. Non-metabolisers differed from the other 
subjects included in the study in ethnicity but not in age, sex, body habitus, blood pressure, heart rate, 
or family history of hypertension. Bimodality of metabolism was suggested by frequency histogram, 
as well  as maximum likelihood and cluster analysis. Among ethnic groups, subjects of  European 
ancestry had the highest frequency of non-metabolism. As part of this study, an in vitro microsomal 
oxidation  experiment  was  performed  to  investigate  the  possible  different  activities  of  the  two 
cytochrome P450 polymorphic variants CYP2D6 and CYP3A4. The results suggested that the major 
route  of  metabolism  of  yohimbine  to  11-hydroxyyohimbine  was  likely  to  occur  via  CYP2D6. 
However,  in  vivo,  both  CYP2D6  and  CYP3A4  were  necessary  to  predict  metabolism.  Non-
metabolisers  had  greater  activation  of  sympathetic  nervous  system  activity.  Yohimbine  increased 
blood  pressure,  an  effect  mediated  haemodynamically  by  elevation  of  cardiac  output  rather  than 
systemic  vascular  resistance.  Blood  pressure  and  cardiac  output  responses  did  not  differ  between 
metaboliser and non-metaboliser groups. 
In  a  randomised,  double-blind,  placebo  controlled  study,  the  effects  of  oral  administration  of 
yohimbine  on  gastrointestinal  transit,  satiation  and  plasma  catecholamines  were  investigated.  The 
possible correlation between sympathetic and gastrointestinal effect of yohimbine and the differences 
in the two cytochrome P450 genotypes, CYP2D6 and CYP3A4, was also studied (Bharucha et al., 
2008).  In  the  study,  30  healthy  volunteers  (15/treatment  group;  25  women  and  5  men)  were 
randomised to yohimbine 16.2 mg orally three times daily or identical placebo for 7 days. Gastric 
emptying,  small  intestinal,  and  colonic  transit  by  scintigraphy,  bowel  habits,  haemodynamics  and 
plasma  catecholamines  were  evaluated.  Genotyping  for  cytochrome  P450  polymorphic  variants 
(CYP2D6  and  CYP3A4)  was  performed  in  25  of  30  subjects  and  the  relationship  between  drug 
metaboliser  status  predicted  by  CYP2D6  and  CYP3A4  and  effects  of  yohimbine  were  assessed. Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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Compared  to  placebo,  yohimbine  increased  diastolic  blood  pressure,  plasma  noradrenaline 
concentrations and maximum tolerated volume during the satiation test. However, yohimbine did not 
affect gastrointestinal transit. Based on CYP2D6 and CYP3A4 alleles, 7 subjects were classified as 
extensive metabolisers and 18 as poor metabolisers of yohimbine. In the group of poor metabolisers, 
yohimbine had a greater increase in plasma noradrenaline, lower maximum tolerated volumes and 
faster  colonic  transit  than  in  the  extensive  metabolisers.  These  data  suggest  that  CYP2D6  and 
CYP3A4 genotypes which determine the metabolism of yohimbine may influence its sympathetic and 
gastrointestinal effects. 
The pharmacokinetic behaviour of (3,5,6-
3H)-raubasine was investigated in five human subjects given 
an oral administration of 240 μg/kg/bw (Marzo et al., 1977). By the oral route, peak plasma levels of 
radioactivity appeared in human subjects 1 hour post dosing. In humans, three-day cumulative urinary 
and faecal excretions of radioactivity accounted respectively for 29 % and 24 % of the dose. 
 
3.1.3.  Summary of ADME data 
There are no data on ADME of alkaloids after administration of yohimbe preparations such as extracts 
in both animals and humans.  
 
The major alkaloid yohimbine, when administered alone in humans, is rapidly absorbed and the oral 
bioavailability  shows  great  variability,  ranging  from  7 %  to  87 %  whereas  an  interindividual 
variability  was  also  found  in  the  pharmacokinetic  parameters  of  yohimbine.  A  rapid  entry  of 
yohimbine into the brain and a slow rate of elimination from serum and brain were observed in rats 
receiving an intravenous administration of yohimbine. In liver, the major biotransformation was via 
CYP2D6 to 11-hydroxy-yohimbine, a metabolite exhibiting similar adrenergic effects than yohimbine. 
Because of the genetic polymorphism of expression of this cytochrome P450, the genotypes  may 
influence the sympathetic and gastrointestinal effects of yohimbine between individuals. The renal 
excretion of yohimbine, 10-hydroxyyohimbine and 11-hydroxyyohimbine were around 0.1, 0.2 and 
14 %, respectively.  
 
Regarding  raubasine,  in  human  subjects  given  tritiated  raubasine  orally,  the  urinary  and  fecal 
excretions  measured  within  three  days  accounted  for  29 %  and  24 %  of  the  radioactive  dose, 
respectively. 
 
3.2.  Toxicological data 
 
3.2.1.  Acute toxicity 
 
3.2.1.1.  Yohimbe bark and its preparations 
No data are available. 
 
3.2.1.2.  Yohimbine and other yohimbe alkaloids 
Mice Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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A dose of 20 mg/kg bw of yohimbine injected subcutaneously (s.c.) in albino male mice (T.T. strain; 
body weight ranging from 18 to 25 g) produced ptosis and slight sedation; the effects lasted for 2 to 4 
hours. Higher doses of yohimbine caused prostration and slightly higher sensitivity. About 30 min 
after  s.c.  injection,  mice  exhibit  intermittent  bouts  of  clonic  convulsions  which  often  continued 
intermittently for several hours (Quinton, 1963). 
Upon i.v. injection, the LD50 for yohimbine in mice was 16 mg/kg bw and 65 mg/kg bw after oral 
exposure (Blaschek et al., 2006). 
 
3.2.2.  Short-term and subchronic toxicity 
No data for yohimbe bark, its preparations and its alkaloids are available. 
 
3.2.3.  Genotoxicity 
 
3.2.3.1.  Yohimbe bark and its preparations 
No  in  vitro  data  are  available  which  allow  to  assess  the  genotoxicity  of  yohimbe  bark  or  its 
preparations. 
A significant increase in the frequency of aneuploids and total chromosomal aberrations in germ cells 
was reported in one study after prolonged (90 days) oral (by gavage) treatment of Swiss albino mice 
with yohimbe bark powder (Al-Majed et al., 2006). However, the Panel noted some major flaws in the 
experimental protocol and data presentation in the work of Al-Majed and co-workers. In particular the 
Panel noted the inclusion of univalents in the computation of chromosomal aberrations in metaphase I 
spermatocytes which is highly influenced by technical artefacts‟ and analyses of aneuploids which 
should  have  been  distinguished  between  hypo-  or  hyperhaploid  metaphase  II  spermatocytes.  In 
addition, the increase in dominant lethal mutations as measured by the pre- and post-implantation loss 
in week 2 after treatment during the entire spermatogenic cycle and not in week 1 after treatment 
cannot be explained. Therefore the Panel considered that no conclusions can be drawn from this study.  
 
3.2.3.2.  Yohimbine and other yohimbe alkaloids 
Raubasine was studied using the SOS Chromotest in E. coli and the induction of gene conversion, 
crossing-over and reverse mutation in the yeast diploid strain XS2316. The authors concluded that 
raubasine is neither genotoxic nor mutagenic nor recombinogenic in microbial systems (von Poser et 
al., 1990). 
No other relevant data on genotoxicity for yohimbine or other alkaloids of yohimbe bark are available. 
 
3.2.4.  Chronic toxicity and carcinogenicity 
No data for yohimbe bark or its preparations are available. However, in a poorly reported study, 
raubasine was administered orally in doses of 0, 5, 10, 20 and 40 mg/kg bw/day to rats (strain not 
specified) for 24 weeks. The authors concluded that, on the basis of measurement of body weight gain, 
examination of blood parameters and histopathological examinations that there was no indication of a 
chronic intoxication (Kroneberg, 1958). Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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3.2.5.  Reproductive and developmental toxicity 
 
3.2.5.1.  Yohimbe bark and its preparations 
In the study by Al-Majed et al. (2006), adult male Swiss albino mice were treated orally (by gavage) 
for 90 days with 0 (controls: 0.3 ml tap water/mouse), 188, 375 or 750 mg/kg bw/day of an aqueous 
suspension of yohimbe bark powder (yohimbine content not specified) of P. yohimbe. In the first and 
second week after treatment, 10 males were mated with 30 untreated females. Each of the following 
parameters  were  evaluated:  reproductive  organ  weight,  motility  and  sperm  count  (20  mice); 
spermatozoa morphology (20 mice); rate of pregnancy and mean implants (total number and number 
of live and dead implants); cytology of testes chromosomes (20 mice); biochemical estimation of 
proteins, RNA, DNA, malondialdehyde (MDA), non-protein sulphhydryl (NP-SH) and hormones. The 
treatment with yohimbe bark powder at 750 mg/kg bw/day caused a significant increase in relative 
weight of the seminal vesicles, decrease in motility and count of spermatozoa, and an increase in the 
number  of  abnormal  spermatozoa.  Furthermore,  an  increase  in  levels  of  estradiol,  prolactin  and 
testosterone was observed. Male fertility was decreased in the first and second week of mating after 
treatment. The pre- and post- implantation loss was increased in the second week of mating; this 
finding cannot be explained as animals were treated for more than an entire spermatogenic cycle. The 
biochemical parameters showed increase of MDA and depletion of NP-SH, proteins, RNA and DNA 
in the testicular cells in the 375 and 750 mg/kg bw/day groups (Al-Majed, 2006). The Panel noted that 
although some of these findings might be indicative of an effect on male reproductive function, no 
definitive conclusions can be drawn from this study due to the inconsistent pattern of results provided 
by the dominant lethal test, in which post-implantation losses were only decreased in matings in week 
two. 
 
3.2.5.2.  Yohimbine and other alkaloids 
No data are available. 
 
3.2.6.  Human data 
 
3.2.6.1.  Yohimbe bark and its preparations 
Case reports 
Ruck et al. (1999) reported a case of a 63-year-old man who exhibited a hypertensive crisis with a 
blood  pressure  of  240/140  mm  Hg,  an  acute  onset  of  severe  headache  and  weakness.  The 
electrocardiogram  showed  a  sinus  tachycardia.  The  man  denied  any  medical  history  including 
hypertension  or  any  prescribed  medicine.  But  he  had  been  taking  a  yohimbine-containing  herbal 
product for treatment of impotence over the previous month (one tablet per mouth daily, as per the 
package directions). No further details are given. 
3.2.6.2.  Yohimbine 
Case reports 
Price et al. (1984) described three patients who experienced yohimbine-induced manic symptoms. 
Yohimbine dose was not clearly identified. Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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In an overview some cases of side effects are mentioned including anxiety and agitation in addition to 
hypertension (Pittler et al., 2005). 
Giampreti et al. (2009) described a 37-year-old bodybuilder who was admitted to the hospital with 
malaise, vomiting, loss of consciousness, and repeated seizures after ingestion of 5 g of yohimbine. He 
was comatose, requiring orotracheal intubation. Blood pressure was 259/107 mmHg and heart rate 140 
beats/min. The yohimbine blood levels at 3, 6, 14, and 22 hours after ingestion were 5 240; 2 250; 
1 530; and 865 ng/ml, respectively, with a mean half-life of 2 hours. The patient recovered without 
sequelae having been treated to increase the elimination of the substance from the body. 
Studies in patients with erectile dysfunction 
There are several studies in patients with erectile dysfunction. Doses of 18 mg were used in the studies 
of Morales et al. (1987) and Riley et al. (1989) and effects have been seen without remarkable non-
intended effects. In the study of Reid et al. (1987) also 18 mg were given with a positive outcome in 
46 % of the 48 patients participating in the study. The dose was individualised in the study of Susset et 
al. (1989), 42 mg/day being the highest dose given. Not all of the 82 patients responded (success rate 
34 %). In 85 patients who took 30 mg a day (two 5 mg tablets three times daily) for eight weeks, seven 
percent rated the tolerability fair or poor without giving details on the side effects (Vogt et al., 1997). 
In a small study (n = 29) drug-related adverse effects occurred in 2 patients in the yohimbine group 
(7 %) when a dose of 36 mg yohimbine per day was given orally for 25 days (Kunelius et al., 1997). In 
a  study  by  Teloken  et  al.  (1998)  100  mg  yohimbine  were  given  to  male  patients  with  erectile 
dysfunction. The authors report that common side effects were anxiety, increase in cardiac frequency, 
increased urinary output and headache.  
In the clinical studies doses of 18 mg/person/day and 100 mg/person/day were given. The intended 
effect was seen in patients treated with those doses.  
The Panel noted that if clinical effects were seen in patients with erectile dysfunction these would 
result from pharmacological action of yohimbine. 
Studies in patients with panic disorders 
In 11 patients with panic disorders, 20 mg yohimbine significantly raised systolic blood pressure (F = 
3.07, p < 0.03), plasma noradrenaline levels (F = 12.11, p < 0.001) and cortisol levels (F = 4.82, p < 
0.02), but had no effect on adrenaline levels (Gurguis, 1997). Noradrenaline responses were similar in 
both groups, but patients had higher cortisol responses to yohimbine than controls (F = 7.14, p < 0.01) 
dose 20 mg. Anxiety scores were also higher after yohimbine dosing.  
Studies in patients with hypertension 
Yohimbine  (0.2  mg/kg bw,  orally)  caused  a  lesser  increase  in  the  plasma  concentrations  of 
noradrenaline in hypertensive patients (+ 67 %) than in normotensive subjects (+ 178 %) and a pressor 
response  in  hypertensive  (but  not  in  normotensive)  patients  (Damase-Michel  et  al.,  1993).  These 
results are consistent with an alteration in the balance of ʱ-adrenoreceptors (for example presynaptic 
ʱ2-adrenoreceptor  desensitisation  and  post-synaptic  ʱ1-adrenoreceptor  hyper-responsiveness)  which 
would help to develop and/or maintain arterial hypertension. 
In the study of Musso et al. (1995), 10 mg yohimbine induced a significant increase in diastolic 
pressure only in the hypertensive patients and not in the healthy controls. Plasma noradrenaline was 
increased  significantly  in  both  yohimbine-treated  groups,  but  the  percent  increase  of  plasma 
noradrenaline after the standing test was decreased significantly only in the healthy yohimbine-treated 
subjects. Plasma dopamine was increased significantly only in the healthy yohimbine-treated subjects.  Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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Studies in patients with orthostatic hypotension 
In 35 patients with severe orthostatic hypotension due to multiple system atrophy or pure autonomic 
failure,  the  effect  of  placebo,  phenylpropanolamine  (12.5  mg  and  25  mg),  yohimbine  (5.4  mg), 
indomethacin  (50  mg),  ibuprofen  (600  mg),  caffeine  (250  mg),  and  methylphenidate  (5 mg)  was 
determined on seated systolic blood pressure. Significant increases in systolic blood pressure can be 
seen in the patients with phenylpropanolamine in low doses or yohimbine or indomethacin (Jordan et 
al., 1998). 
Studies in healthy volunteers 
In  a  study  by  Galitzky  et  al.  (1988)  in  fasting  healthy  subjects  oral  yohimbine  administration 
(0.2 mg/kg bw) produced elevated plasma concentrations of noradrenaline, glycerol and non-esterified 
fatty acids without significant action on heart rate or blood pressure during the time-course of the 
experiment. The same group showed that the same reaction was seen in obese and non-obese women 
with the same dose (oral yohimbine administration, 0.2 mg/kg bw) (Berlan et al., 1991). This dose 
induced lipid mobilization (increase in plasma non-esterified fatty acids) without significant action on 
plasma glucose, insulin levels, heart rate or blood pressure during the time-course of the experiment 
(240 min). Plasma noradrenaline (but not adrenaline) concentrations were increased (100 %) after oral 
yohimbine administration.  
In a study in healthy young volunteers oral yohimbine (20 or 40 mg) causes dose-dependent increases 
in blood pressure, heart rate, and plasma noradrenaline. The data indicated that yohimbine increases 
plasma noradrenaline levels by increasing the rate of noradrenaline release from sympathetic nerves, 
and probably increases adrenaline release from the adrenals (Murburg et al., 1991). The results are in 
agreement with previous studies. 
The effect of the selective ʱ2-adrenergic receptor antagonist yohimbine on platelet aggregation was 
evaluated  in  healthy  subjects  (Berlin  et  al.,  1991).  Yohimbine  administered  orally  selectively 
antagonised adrenaline but not collagen, arachidonic acid, or adenosine diphosphate-induced ex vivo 
platelet aggregation. The lowest dose of yohimbine that significantly inhibited adrenaline-induced 
platelet aggregation was 8 mg. The inhibitory effect of yohimbine on platelet aggregation lasted 10 h 
with the 12 mg dose. At the doses studied (4, 8, and 12 mg), yohimbine did not modify blood pressure, 
standing heart rate, or plasma catecholamine or glucose concentrations. A dose of 12 mg of yohimbine 
moderately but significantly accelerated supine heart rate (mean maximal increase, 7 ± 3 beats/min). 
The effects of oral administration of the ʱ2-adrenergic receptor antagonists yohimbine (20 mg) were 
tested concerning the effects on mood and anxiety states, physiological indexes, plasma cortisol levels, 
and plasma levels of the noradrenaline metabolite MHPG (Krystal et al., 1992). Yohimbine had a 
similar profile as the comparator idazoxan which increased plasma MHPG, plasma cortisol, systolic 
and diastolic blood pressure, and Panic Attack Symptom Scale scores in healthy subjects.  
Impulsivity was assessed in healthy volunteers using the Immediate and Delayed Memory Tasks after 
one or two doses of yohimbine (Swann et al., 2005). Doses of yohimbine were titred according to the 
blood pressure response and doses up to 40 mg/h were given. Yohimbine was associated with a dose-
related increase in impulsive Immediate Memory Tasks commission errors, with an increase of > 50 % 
relative to baseline at the higher dose as compared to placebo.  
3.2.6.3.  Raubasine 
Studies in patients 
Raubasine has been used in a variety of clinical conditions. The clinical studies were performed at 
times in which detailed description of patients and endpoints was not in use and also the systematic 
evaluation of the patients concerning possible adverse effects was not part of an evaluation of a new Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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treatment and therefore the publications are less suited to get information on the effects of raubasine in 
humans. Nevertheless the studies which have been found in a literature search are reported here.  
In explorative studies 18 patients with peripheral arterial disease of various origins have been treated 
with 3 mg raubasine daily by the oral route (Pieri et al., 1957). Further 9 patients, with tachycardia and 
hypertension because of Basedow‟s disease, were also treated with the same dosage. No details on the 
patients and only same examples of clinical details are given. The authors do not report whether 
adverse effects have been observed.  
Pieri et al. (1958) published a case series of 92 patients in which raubasine was given at daily doses of 
3 mg and in some patients of 5 mg by the oral route. The patients suffered from coronary heart 
disease, hypertension and symptoms of cerebral arterial disease. No adverse effects were noted.  
A case series of 13 patients was reported by Robert (1962) in which raubasine (Hydrosarpan
®) was 
used to lower the elevated blood pressure. No dosage schedule is given in the publication and no data 
are given concerning possible adverse effects. 
In a study in 65 patients with peripheral arterial disease (Starace and Noferi, 1963) raubasine was 
given in daily doses of 4-8 mg intravenously or 8-12 mg orally, divided in 2-3 doses. No side effects 
were observed besides gastric discomfort even when the treatment lasted up to 40-60 days.  
In 22 patients with peripheral arterial disease of the lower extremities and five patients with peripheral 
arterial disease of the upper extremities the effects of raubasine (3 times 5 mg for 3 weeks orally) was 
investigated (Perrin, 1965). The author reported that one patient had to withdrawn from the study 
because of adverse effects which were manifested as burning pain of the stomach.  
Pluvinage  (1965)  carried  out  a  study  in  30  patients  with  different  neurological  and  psychiatric 
diseases. The patients received 15 to 60 mg of raubasine daily for 3 weeks by the oral route. The 
author reported on blood pressure changes (decline of 10 to 20 mmHg) which after 10 to 20 days 
returned  to  pre-trial  values.  Other  non-therapeutic  effects  have  not  been  reported.  The  clinical 
judgment  on  the  improvement  was  descriptive  without  clear  endpoints  and  changes  in 
electroencephalograms were also reported.  
In another study, 100 patients with chronic arterial disease were treated with raubasine (Lamuran
®), 
20 mg orally, three times daily, for three weeks (Koch and Eide, 1972). No adverse effects were 
reported besides one case of allergic dermal reaction. The authors also reported that they observed a 
fall in blood pressure in patients in which the drug was given until the day where they underwent 
anaesthesia because of vascular surgery. No other details were reported. 
Studies in healthy volunteers 
Healthy volunteers received infusions of 20 mg and 40 mg raubasine of 5 minutes duration. Cardio-
vascular  parameters  were  measured  (Molzahn  and  Lohmann,  1973).  A  dose  of  20  mg  raubasine 
elicited  only  slight  effect  on  cardiac  output  (8 %  increase)  whereas  immediately  after  the  end  of 
infusion of 40 mg, cardiac output, heart rate and peripheral venous pressure increased and caused a fall 
of  central  venous  pressure.  As  a  reflex  reaction,  arterial  pressure  was  increased  after  15  and  30 
minutes. No subjective side effects were reported in the publication. 
The study of Neuman et al. (1986) investigated the effect of raubasine on platelet biological function 
in 14 patients in an ex vivo experiment with adenosine diphosphate (2.5 and 5.0 x 10
-6 mol/l), collagen 
(0.05 mg/ml), and adrenaline (1.68 x 10
-4 mol/l) as inducing agents. The patients received 3 times 
20 mg  raubasine,  orally, daily  for  six  weeks.  In  12  out  of  the  14  patients  a  reduction  in  platelet 
aggregation in at least 2 of the 3 test curves was observed. This reduction was statistically significant 
for collagen (p < 0.02) and adrenaline (p < 0.01). A statistically significant (p < 0.05) prolongation of 
the latency period of aggregation produced by collagen was found in 12 out of 14 patients and a Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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prolongation of recalcification time produced by the reduction in platelet factor 3 was found in 9 out 
of 14 patients. The patients underwent clinical and standard blood tests. The authors reported that no 
remarkable results were observed. 
Raubasine appears not to show subjective and objective adverse effects in doses less than 10 mg daily 
(approximately 0.15 mg/kg bw/day) when given orally. 
 
3.2.6.4.  Other yohimbe bark alkaloids 
No data are available.  
 
3.2.7.  Mode of action of yohimbine and raubasine 
Yohimbine is an antagonist acting at ʱ2-adrenoreceptors which enhances noradrenaline release and 
increases  sympathetic  activity.  ʱ2-adrenoreceptors  are  found  in  the  vasculature.  Postsynaptic  ʱ2-
adrenoreceptors have been identified by Jie et al. (1984). The same group also provided evidence for 
the existence of presynaptic ʱ2-adrenoreceptors (Jie et al., 1987). ʱ2-adrenoreceptors are also found in 
the central nervous system. Hence, the effects on blood pressure, heart rate and central nervous effects 
seen after yohimbine administration are explained by its effect on the ʱ2-adrenoreceptors.  
Raubasine is an alkaloid which possesses pre- and postsynaptic ʱ-adrenoreceptor blocking activity. Its 
postsynaptic blocking properties are more pronounced than that of yohimbine as shown in the rat vase 
deference model (Demichel et al., 1981). In the pithed rat it preferentially acts at ʱ1-adrenoreceptors 
but has also blocking activity at the ʱ2-adrenoreceptors. Compared to yohimbine which mainly blocks 
the ʱ2-adrenoreceptors the activity of raubasine at the ʱ2-adrenoreceptor is low (Demichel et al., 1982; 
Roquebert and Demichel, 1984). 
 
4.  Discussion 
EFSA was asked to  assess the safety in use of Yohimbe and its preparations when consumed as 
component of food, e.g. in food supplements. The risk assessment is carried out according to the 
EFSA Guidance on safety assessment of botanicals and botanical preparations intended for use as 
ingredients in food supplements (EFSA SC, 2009).  
Concerns had been raised by an EU Member State Authority regarding a potential risk to consumers 
linked with the intake of yohimbe bark extracts containing products to treat sexual dysfunction and 
erectile problems. Consequently, the Commission has initiated the procedure under Article 8 (2) of 
Regulation  (EC)  No  1925/2006  on  the  addition  of  vitamins  and  minerals  and  of  certain  other 
substances to foods, for Yohimbe. Therefore EFSA has been asked to review the relevant existing 
scientific data on the possible link between the intakes of Yohimbe and a harmful effect on health and 
to provide advice on a tolerable upper intake level (UL) for Yohimbe, for the general population, and 
as appropriate, for vulnerable subgroups of the population. In the absence of an UL, advice on a daily 
intake  of  Yohimbe  that  does  not  give  rise  to  concerns  about  harmful  effects  to  health  should be 
provided.  
In addressing the Terms of Reference, the Panel noted that the term “tolerable upper intake level” was 
used by EFSA so far only for nutrients, such as vitamins or minerals, to describe the maximum level 
of total chronic daily intake judged to be unlikely to pose a risk of adverse health effects to humans. 
The Panel considered that the use of this term may not be appropriate for botanicals and botanical 
preparations being constituents of food supplements or other food products, especially in cases where 
the botanicals/botanical preparations or their main components have known medical uses based on 
scientifically  established  pharmacological  properties  and/or  where  the  botanicals/botanical Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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preparations cannot be regarded as a component of the normal diet. Using the term “tolerable upper 
intake level” for botanicals and botanical preparations could lead to the misinterpretation that they 
could play a similar role in human nutrition as minerals and vitamins, which differ from them inter alia 
in being in general constituents of the normal diet and in being in many cases essential. 
Food supplements containing yohimbe bark or its preparations are commercially available to improve 
sexual  and  athletic  performance  and  for  the  enhancement  of  sexual  satisfaction.  The  use  of  such 
products is also promoted for weight loss. According to the information provided by the EHIA and the 
ERNA, in general these products are not marketed in Europe. The Panel however noted that they are 
offered via internet, often in combination with other substances (e.g. caffeine). 
Yohimbe bark consists of dried bark of the trunk and branches of P. yohimbe. Toxicologically relevant 
compounds of yohimbe bark are indole alkaloids. Total alkaloid content data vary, depending on a 
number of botanical and environmental factors. Also, depending on the analytical method used results 
of analysis may vary to a high degree. The major alkaloid is yohimbine, accompanied by a number of 
stereoisomers and other related compounds which are associated with proven or potential biological 
activity (e.g. raubasine). The reported value of total alkaloid content of the bark varies over a wide 
range, from about 5 to over 150 mg/g, with a value around 10 mg/g being most often found for 
yohimbine whereas for the individual stereoisomers of yohimbine the reported values are in the range 
of 0.3 to 4.6 mg/g. The concentration of raubasine and corynantheine is reported to be around 0.4 
mg/g and 0.05 mg/g, respectively. 
No specifications for yohimbe bark or its preparations such as extracts for the use in food are known 
nor is there information on standardisation of the extracts for use in food with regard to the ratio of 
extracted material to starting material, extraction solvent or content of biologically active ingredients.  
There  are  no  official  inter-laboratory  validated  methods  for  determination  of  yohimbine  and 
accompanying alkaloids in food, although a single-laboratory validated method for the determination 
of yohimbine in commercial products has been described. 
The actual content of yohimbine versus the declared quantity in the label of food supplements was 
measured in studies carried out in the US. The results showed that yohimbine levels greatly vary 
among  the  different  products  and  that  information  reported  on  the  label  of  the  existing  food 
supplements do not generally correspond with the quantities analytically determined.  
Regarding the specifications, the Panel noted that quantitative data for alkaloids other than yohimbine 
in yohimbe bark preparations in food supplements are missing but would be needed in view of their 
known or potential biological activity.  
Yohimbine is an antagonist acting at ʱ2-adrenoreceptors, which enhances noradrenaline release and 
increases sympathetic activity. Pre- and postsynaptic ʱ2-adrenoreceptors have been identified and ʱ2-
adrenoreceptors are also found in the central nervous system. Hence, the effects on blood pressure, 
heart rate and central nervous effects seen after yohimbine administration are explained by its effect 
on the ʱ2-adrenoreceptors. Raubasine acts mainly as an antagonist of ʱ1-adrenoreceptors.  
The pharmaceutical use of yohimbe bark and preparations thereof is described in older literature. At 
present,  in  the  European Union  the  only  existing monograph  (Commission  E)  states  that  there is 
insufficient proof of efficacy and the unforeseeable correlation between risk and benefit. According to 
information made available by the EMA, no assessment report on safety and efficacy is available or 
currently  expected  from  the  HMPC  since  yohimbe  bark  is  not  on  the  HMPC  priority  list.  It  is 
important to note that this lack of priority is a consequence of the known risks associated with the use 
of yohimbe bark and its preparations as herbal medicinal product. 
For  the  main  alkaloid  yohimbine,  authorised  medicinal  products  exist,  containing  yohimbine 
hydrochloride as active ingredient. It is given orally in the treatment of erectile dysfunction in doses of Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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5 10 mg, 2 3 times daily, the typical treatment period being 8 weeks. Concerning contraindications 
and warnings the following conditions are mentioned: hypersensitivity to the active ingredient, cardiac 
disorders  (especially  heart  disease,  tachycardic  arrhythmia),  hypertension,  hypotension,  greatly 
impaired  kidney  or  liver  function,  ulcer  (stomach  or  intestine),  glaucoma,  psychiatric  disorders, 
particularly mood disorders and anxiety as well as concomitant use of central nervous acting drugs. 
Because no adequate clinical experiences with treatment in women exist it is also not possible to 
determine  effects  on  a  fetus  during  pregnancy.  Adverse  effects  listed  in  the  summary  of  product 
characteristics  are:  headache,  nausea,  increased  urinary  urge;  insomnia,  anxiety,  restlessness, 
irritability  (common);  increase  of  blood  pressure  and  pulse  rate,  palpitation,  dizziness,  vomiting, 
anorexia,  gastric  complaints,  diarrhoea,  flush,  sweating,  shivering,  allergic  reactions,  nervousness 
(uncommon); hypotension, tremor, bronchospasm, dysuria, decreased urge, genital pains, exanthema 
(very rare). 
The  alkaloid  raubasine  given  orally  is  used  as  an  adjuvant  in  the  treatment  of  peripheral  arterial 
disorders.  The  dose  is  10 20  mg,  2 3  times  daily.  Contraindications  and  warnings  include 
hypersensitivity to the active substance, serious heart disease, haemorrhagic syndrome or intracranial 
hypertension, uncompensated heart failure, valvular stenosis, significant reduction of the pulmonary 
circulatory bed, glaucoma, the first three months of pregnancy and the usage during or within two 
weeks after treatment with monoaminooxidase inhibitors. Adverse effects listed in the summary of 
product characteristics are: dizziness, hypotension, sweating, flushing (rare), appearance of confusion, 
tachycardia, nausea, allergic reactions (occasionally). In the case of heart disease or other general 
disorders discontinuation of therapy may be required. 
As for national regulations the use of yohimbe bark and its preparations is specifically prohibited in 
foods  and  food  supplements,  in  several  European  countries  (e.g.  United  Kingdom,  Netherlands, 
Belgium, Denmark, Czech Republic), as well as in Canada, Australia and New Zealand. 
It was not possible to assess exposure to yohimbe bark and its preparations due to lack of data. An 
exposure assessment to yohimbine from food supplements containing yohimbe bark was performed 
using  data  available  from  the  literature.  Quantitative  data  for  alkaloids  other  than  yohimbine  in 
yohimbe bark containing food supplements are missing and, therefore, no exposure assessment could 
be  performed  for  them.  These  data  would  be  specially  needed  for  substances  with  known 
pharmacological activity, e.g. raubasine.  
The maximum dose of yohimbine estimated from a single serving of food supplement (18.8 mg, see 
Table 3) was higher than the highest single dose of authorised medicinal products (10 mg, see Table 
4). Maximum daily exposure to yohimbine from food supplements has been estimated to be up to 75 
mg/person,  which  is  higher  than  the  maximum  approved  daily  dose  of  yohimbine  from  use  as  a 
medicinal product (up to 30 mg/person, see Table 4). 
In general botanicals such as yohimbe bark and botanical preparations such as yohimbe bark extracts 
for use in food supplements should be evaluated based on existing data on the chemical specifications 
and  existing  toxicological  data,  including  read  across  where  appropriate,  for  the  individual 
botanical/botanical  preparation.  Therefore,  the  Panel  gave  priority  to  the  toxicological  studies 
investigating  yohimbe  bark  and  its  preparations  and  then  on  yohimbine  as  the  main  alkaloid  in 
yohimbe bark and the only alkaloid for which occurrence had been shown and quantified in food 
supplements containing yohimbe bark.  
There  are  no  available  data  describing  the  ADME  of  yohimbe  alkaloids  after  administration  of 
yohimbe  bark  preparations,  such  as  extracts.  In  an  in  vitro  study,  the  alkaloids  of  yohimbe  bark 
extract, yohimbine, raubasine, and corynanthine have been described to be transported across human 
Caco-2  cells  monolayers  (Ma  and  Yang,  2008).  When  administered  alone  in  humans,  the  major 
alkaloid yohimbine is rapidly absorbed and the oral bioavailability ranged from 7 % to 87 % (Guthrie 
et  al.,  1990).  The  great  variability  of  absorption  of  yohimbine  in  humans  would  be  due  to  both 
interindividual and dietary factors. In terms of distribution, a rapid entry of yohimbine into the brain Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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and a slow rate of elimination from serum and brain were observed in rats receiving an intravenous 
administration  of  yohimbine  (Hubbard  et  al.,  1988).  In  humans,  there  is  a  significant  correlation 
between plasma noradrenaline levels and yohimbine AUC or Cmax (Sturgil et al., 1997). In liver, the 
major  biotransformation  was  oxidation  to  11-hydroxyyohimbine,  a  metabolite  exhibiting  similar 
adrenergic effects as yohimbine. This route of metabolism was found to depend on the cytochrome 
P450 polymorphic variants CYP2D6 and CYP3A4, causing interindividual differences in sympathetic 
and gastrointestinal effects of this alkaloid, as clinically observed in humans. In humans, the renal 
excretion of yohimbine, 10-hydroxyyohimbine and 11-hydroxyyohimbine were around 0.1, 0.2 and 
14 %, respectively. There are only a few data on disposition of raubasine. In human subjects given 
tritiated raubasine orally, the urinary and fecal excretions of radioactivity measured for three days 
accounted respectively for 29 % and 24 % of the dose (Marzo et al., 1977). 
No short-term or (sub)chronic toxicity and carcinogenicity studies on yohimbe bark or its preparations 
were available. 
In a limitedly reported study, raubasine was administered by gavage to rats at doses of 0, 5, 10, 20 and 
40 mg/kg bw/day for 24 weeks. No effects on body weight, haematology and histopathology were 
observed (Kroneberg, 1957). 
No  in  vitro  data  on  genotoxicity  studies  of  yohimbe  bark,  its  preparations  or  of  yohimbine  are 
available. The Panel noted the results of a genotoxicity assay in germ cells of male mice which was 
performed after 90 days of treatment with an aqueous suspension of yohimbe bark powder (yohimbine 
content not specified). However, major flaws in the experimental protocol and in the presentation of 
the data prevented the Panel from considering this study for risk assessment. 
In the same study, a number of parameters of male fertility were also measured, however the Panel 
had reservations about this study and considered that no conclusions could be drawn concerning the 
reproductive toxicity of yohimbe bark. 
Raubasine  was  negative  in  the  SOS  Chromotest  in  E. coli  and  did  not  induce  gene  conversion, 
crossing-over or reverse mutations in the yeast diploid strain XS2316 (von Poser et al., 1990).  
Regarding human data on the use of yohimbe bark extract, only one case report has been found in the 
literature. Ruck et al. (1999) reported a case of a 63-year-old man who exhibited a hypertensive crisis 
following administration of a yohimbine-containing herbal product.  
No clinical studies investigating effects of yohimbe bark or its preparations are available, thus the 
Panel considered the following evidence coming from studies on yohimbine and raubasine. No human 
data were found for other yohimbe bark alkaloids. 
Human data encompass several case reports with yohimbine intoxications for which severe symptoms 
(hypertensive crisis, manic symptoms, anxiety, agitation, loss of consciousness) have been described 
(Price et al., 1984; Pittler et al., 2005; Giampreti et al., 2009). Clinical studies have been performed in 
a whole array of indications such as erectile dysfunction (Morales et al., 1987; Riley et al., 1989; 
Susset et al., 1989; Kunelius et al., 1997; Vogt et al., 1997; Teloken et al.,1998), panic disorders 
(Gurguis,  1997),  hypertension  (Damase-Michel  et  al.,  1993;  Musso  et  al.,  1995)  and  orthostatic 
hypotension (Jordan et al., 1998). Doses between 5.4 mg and 100 mg daily were used whereby doses 
up to 18 mg daily elicited no subjective side effects but doses as low as 5.4 mg resulted in significant 
increases in systolic blood pressure (Jordan et al., 1998). Several studies in healthy volunteers have 
been carried out investigating various endpoints. Plasma concentrations of noradrenaline, glycerol and 
non-esterified fatty acids were increased (Galitzky et al., 1988; Berlan et al., 1991) as was also blood 
pressure  and  heart  rate  (Murburg  et  al.,  1991).  Furthermore,  antagonising  of  adrenaline-induced 
platelet aggregation was  shown (Berlan et al. 1991). Mood, anxiety states, physiological indexes, 
plasma  cortisol  levels,  and  plasma  levels  of  the  noradrenaline  metabolite  3-methoxy-4-
hydroxyphenylethylene  glycol  was  influenced  by  20  -  40  mg  yohimbine  (Krystal  et  al.,  1992). Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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Yohimbine was associated with a dose-related increase in impulsive omission errors (Swann et al., 
2005).  In  these  studies  in  healthy  volunteers  8  mg  was  active  to  antagonise  platelet  aggregation 
without  modifying  blood  pressure,  standing  heart  rate,  or  plasma  catecholamine  or  glucose 
concentrations. Twelve milligrams of yohimbine moderately but significantly accelerated supine heart 
rate (mean maximal increase, 7 ± 3 beats/min).  
The  effects  which  were  observed  with  the  single  alkaloid  yohimbine  may  also  be  observed  after 
yohimbe  bark  intake.  However,  there  are  no  data  allowing  an  extrapolation  of  the  dose-response 
relationship observed after yohimbine to the mixture of substances contained in yohimbe bark. This 
limits the use of the human data of yohimbine in the risk assessment of yohimbe bark. 
In the human studies evaluated in the present opinion, raubasine did not show adverse effects in oral 
doses less than 10 mg/person/day (corresponding to approximately 0.15 mg/kg bw/day). 
Overall the Panel noted the following: 
  Yohimbe bark preparations are available worldwide as food supplements via internet retailing. 
  In West Africa, yohimbe bark preparations were traditionally used e.g. as a general tonic, as a 
performance enhancer for athletes and as an aphrodisiac.  
  In general, botanicals such as yohimbe bark and botanical preparations such as yohimbe bark 
extracts  for  use  in  food  supplements  should  be  evaluated  based  on  existing  data  on  the 
chemical  specifications  and  existing  toxicological  data,  including  read  across  where 
appropriate, for the individual botanical/botanical preparation. 
  Quantitative data for alkaloids other than yohimbine in yohimbe bark preparations in food 
supplements are not available but are required in view of their known or potential biological 
activity. 
  No  specifications  for  yohimbe  bark  or  its  preparations  such  as  extracts  used  in  food 
supplements are known. There is no information on standardisation of the extracts for use in 
food supplements with regard to the ratio of extracted material to starting material, extraction 
solvent or content of biologically active ingredients. 
  There are no official inter-laboratory validated methods for determination of yohimbine and 
accompanying alkaloids in food supplements, although a single-laboratory validated method 
for the determination of yohimbine in commercial products has been described. 
  In several European countries, the use of yohimbe bark and its preparations is specifically 
prohibited in foods and food supplements. 
  According to information made available by the European Medicines Agency, no assessment 
report on safety and efficacy is available or currently expected from the Committee on Herbal 
Medicinal  Products  (HMPC)  since  yohimbe  bark  is  not  on  the  HMPC  priority  list.  It  is 
important to note that this lack of priority is a consequence of the known risks associated with 
the use of yohimbe bark and its preparations as herbal medicinal product.  
  According to information made available by the EMA, no single ingredient (traditional) herbal 
medicinal products containing yohimbe bark or its preparations appear to be authorised or 
registered within the EU. 
  For the main alkaloid yohimbine medicinal usage exists in the form of its hydrochloride. It is 
given orally in the treatment of erectile dysfunction in doses of 5 10 mg, 2 3 times daily, for 
a typical treatment period of 8 weeks. The alkaloid raubasine is given orally as adjuvant in the 
treatment of peripheral arterial disorders in doses of 10 20 mg, 2 3 times daily. 
  Maximum daily exposure to yohimbine from food supplements has been estimated by the 
Panel to be up to 75 mg/person, which is higher than the approved daily dose of yohimbine 
from use as a medicinal product (up to 30 mg/person). 
  Based  on  structural  considerations  co-exposure  to  yohimbine  and  other  yohimbe  bark 
alkaloids may be interacting.  
  No data are available describing the ADME of Yohimbe alkaloids after administration of 
yohimbe bark preparations such as extracts.  Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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  When administered alone in humans, the major alkaloid yohimbine is rapidly absorbed and the 
oral bioavailability ranged very widely from 7 % to 87 %. 
  In  humans,  the  major  hepatic  oxidation  of  yohimbine  to  its  pharmacologically  active  11-
hydroxy metabolite is depending on two cytochrome P450 polymorphic variants CYP2D6 and 
CYP3A4.  The  differences  in  metabolite  production  result  in  clinically  observed 
interindividual variability in sympathetic and gastrointestinal effects of this alkaloid. 
  No experimental data on subchronic or chronic toxicity and carcinogenicity of yohimbe bark, 
its preparations or of yohimbine are available. 
  No in vitro data on genotoxicity studies of yohimbe bark, its preparations or of yohimbine are 
available.  
  An in vivo genotoxicity assay in germ cells of male mice was performed after 90 days of 
treatment with yohimbe bark showed some major flaws in experimental protocol and data 
presentation and no conclusions could be drawn from this study.  
  The Panel considered that this study could not be used for the assessment of male fertility and 
that no adequate experimental data on reproductive and developmental toxicity of yohimbe 
bark, its preparations or of yohimbine are available. 
  No clinical studies investigating effects of yohimbe bark or its preparations are available, thus 
evidence coming from studies on yohimbine and raubasine was considered. No human data 
were found for other yohimbe bark alkaloids. 
  Available data of a case report on a hypertensive crisis after intake of a yohimbine-containing 
herbal  product  for  treatment  of  impotence  over  the  past  month  are  indicative  of  possible 
severe side effects of yohimbine. However, based on the information provided in this single 
case report, it is not possible to ascertain the frequency of occurrence. 
  Adverse  effects  listed  in  the  summary  of  product  characteristics  for  medicinal  products 
containing  yohimbine  are:  headache,  nausea,  increased  urinary  urge;  insomnia,  anxiety, 
restlessness,  irritability  (common);  increase  of  blood  pressure  and  pulse  rate,  palpitation, 
dizziness,  vomiting,  anorexia,  gastric  complaints,  diarrhoea,  flush,  sweating,  shivering, 
allergic  reactions,  nervousness  (uncommon);  hypotension,  tremor,  bronchospasm,  dysuria, 
decreased urge, genital pains, exanthema (very rare). 
  Several of these effects have also been shown in clinical studies of yohimbine. In a study in 
healthy young volunteers oral yohimbine (20 or 40 mg) caused dose-dependent increases in 
blood pressure, heart rate, and plasma noradrenaline concentration.  
  According to a study in healthy human volunteers, a single oral dose of 4 mg yohimbine 
/person did not show effects on platelet aggregation and cardiovascular parameters as well as 
plasma catecholamines and glucose concentrations.  
CONCLUSIONS  
The present opinion deals with the safety of the bark from Pausinystalia yohimbe (K. Schum.) Pierre 
ex Beille and preparations made from it when used in food, e.g. in the form of food supplements. 
Overall the missing information include quantitative data on the composition and specifications of 
yohimbe bark and its preparations used in food and food supplements covering other alkaloids besides 
yohimbine, data on the bioavailability of active ingredients from the yohimbe bark extract and data on 
the toxicity of well specified individual preparations of yohimbe bark and the major yohimbe bark 
alkaloids, especially regarding subchronic toxicity, genotoxicity and reproductive toxicity. 
The Panel concluded that according to the Guidance on safety assessment of botanicals and botanical 
preparations intended for use as ingredients in food supplements (EFSA SC, 2009) yohimbe bark and 
its preparations belong to the category of botanicals/botanical preparations for which the available data 
are not sufficient to conclude on their safety or to establish a health based guidance value (safety 
assessment based on available knowledge (Level A) revealed need for further data).  Yohimbe (P. yohimbe (K. Schum) Pierre ex Beille) for use in food    
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The Panel concluded that based on the information on the use of yohimbe bark and its preparations in 
food supplements, estimated exposure to yohimbine could be similar to or higher than that at which 
effects were reported from  the use of yohimbine in medicinal products. 
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ABBREVIATIONS 
ANS Panel:    Panel on Food Additives and Nutrient Sources Added to Food 
APCI:      atmospheric pressure chemical ionisation  
AUC:      area under the concentration-time curve  
BfR:      German Federal Institute for Risk Assessment  
Cmax:      maximal concentration 
EEA:      European Economic Area 
EFSA:      European Food Safety Authority 
EHIA:      European Herbal Infusions Association 
EMA:       European Medicines Agency 
ERNA:     European Responsible Nutrition Alliance 
ESI:      electrospray ionisation 
ESI:      electrospray ionisation 
EU:      European Union 
GC:      gas chromatography 
HMPC:     Committee on Herbal Medicinal Products 
HPLC:     high performance liquid chromatography 
i.p.:      intraperitoneal 
i.v.:      intravenous 
LOD:      limit of detection 
LOQ:      limit of quantitation  
MDA:      malondialdehyde 
MHPG:     3-methoxy-4-hydroxyphenylethylene-glycol 
MS:      mass spectrometry  
NACE:     non-aqueous capillary electrophoresis 
NPD:      nitrogen-phosphorous detector  
NP-SH:     non-protein sulphhydryl 
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s.c.:      subcutaneous 
TLC:      thin layer chromatography 
UHPLC:    ultra high-performance liquid chromatography 
UL:      tolerable upper intake level 
UPLC:     performance liquid chromatography 
UV:       ultra -ultraviolet 
Vss:      steady-state volume of distribution 